Loading organization details...
Loading organization details...
EMORY UNIVERSITY'S MISSION IS TO CREATE, PRESERVE, TEACH, AND APPLY KNOWLEDGE IN THE SERVICE OF HUMANITY AND TO PROVIDE EXCELLENCE IN PATIENT CARE.
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$7.3B
Program Spending
93%
of total expenses go to program services
Total Contributions
$1.2B
Total Expenses
▼$6.6B
Total Assets
$22.2B
Total Liabilities
▼$6.2B
Net Assets
$16B
Officer Compensation
→$43.5M
Other Salaries
$2.4B
Investment Income
$763.9M
Fundraising
▼$202.4K
Tax Year 2023 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $240.2M
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
SAINT JOSEPH'S HOSPITAL OF ATLANTA INC58-0566257 | Atlanta, GA | $35.5M | Cash | GRANT |
EMORYSAINT JOSEPH'S INC45-2721833 | Atlanta, GA | $34.8M | Cash | GRANT |
ORASURE TECHNOLOGIES INC36-4370966 | PHILADELPHIA, PA | $11.1M | Cash | RESEARCH/SUBCONTRACT |
GEORGIA TECH RESEARCH CORPORATION58-0603146 | ATLANTA, GA | $9.6M | Cash | RESEARCH/SUBCONTRACT |
FRED HUTCHINSON CANCER CENTER91-1935159 | SEATTLE, WA | $7.9M | Cash | RESEARCH/SUBCONTRACT |
CHILDREN'S HEALTHCARE OF ATLANTA INC58-2367819 | ATLANTA, GA | $6.5M | Cash | RESEARCH/SUBCONTRACT |
| ATHENS, GA | $4.9M | Cash | RESEARCH/SUBCONTRACT | |
OKLAHOMA MEDICAL RESEARCH FOUNDATION73-0580274 | OKLAHOMA CITY, OK | $4.8M | Cash | RESEARCH/SUBCONTRACT |
DCN DIAGNOSTICS20-5531959 | CARLSBAD, CA | $4.7M | Cash | RESEARCH/SUBCONTRACT |
HJF MEDICAL RESEARCH INTERNATIONAL INC52-2322791 | BETHESDA, MD | $4M | Cash | RESEARCH/SUBCONTRACT |
THE MOREHOUSE SCHOOL OF MEDICINE58-1438873 | ATLANTA, GA | $4M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF NEBRASKA BOARD OF REGENTS47-0049123 | LINCOLN, NE | $3.7M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF MARYLAND52-6002033 | COLLEGE PARK, MD | $3.4M | Cash | RESEARCH/SUBCONTRACT |
| ATLANTA, GA | $3.3M | Cash | RESEARCH/SUBCONTRACT | |
FAMILY HEALTH INTERNATIONAL23-7413005 | DURHAM, NC | $3.1M | Cash | RESEARCH/SUBCONTRACT |
YALE UNIVERSITY | NEW HAVEN, CT | $2.7M | Cash | RESEARCH/SUBCONTRACT |
GRADY MEMORIAL HOSPITAL CORPORATION26-2037695 | ATLANTA, GA | $2.6M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF WASHINGTON91-6001537 | SEATTLE, WA | $2.5M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF PITTSBURGH25-0965591 | PITTSBURGH, PA | $2.5M | Cash | RESEARCH/SUBCONTRACT |
| CHICAGO, IL | $2.5M | Cash | RESEARCH/SUBCONTRACT | |
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY94-1156365 | REDWOOD CITY, CA | $2.3M | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF MICHIGAN38-6006309 | ANN ARBOR, MI | $2.3M | Cash | RESEARCH/SUBCONTRACT |
| PHILADELPHIA, PA | $2.3M | Cash | RESEARCH/SUBCONTRACT | |
THE GENERAL HOSPITAL CORPORATION | SOMERVILLE, MA | $2.2M | Cash | RESEARCH/SUBCONTRACT |
CENTERS FOR DISEASE CONTROL & PREVENTION58-6051157 | ATLANTA, GA | $2.1M | Cash | RESEARCH/SUBCONTRACT |
DUKE UNIVERSITY56-0532129 | DURHAM, NC | $2.1M | Cash | Subcontract/Sponsorship |
| WESTBURY, NY | $2M | Cash | RESEARCH/SUBCONTRACT | |
| CHAPEL HILL, NC | $1.9M | Cash | RESEARCH/SUBCONTRACT | |
UNIVERSITY OF ALABAMA AT BIRMINGHAM63-6005396 | BIRMINGHAM, AL | $1.9M | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF MINNESOTA41-6007513 | MINNEAPOLIS, MN | $1.8M | Cash | RESEARCH/SUBCONTRACT |
| NEW YORK, NY | $1.4M | Cash | RESEARCH/SUBCONTRACT | |
GEORGIA STATE UNIVERSITY FOUNDATION INC58-6033185 | ATLANTA, GA | $1.4M | Cash | RESEARCH/SUBCONTRACT |
RHO FEDERAL SYSTEMS DIVISION INC56-1927659 | DURHAM, NC | $1.4M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF FLORIDA59-6002052 | GAINESVILLE, FL | $1.4M | Cash | RESEARCH/SUBCONTRACT |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI13-6171197 | NEW YORK, NY | $1.3M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON74-6000949 | GALVESTON, TX | $1.3M | Cash | RESEARCH/SUBCONTRACT |
KAISER FOUNDATION HOSPITALS94-1105628 | OAKLAND, CA | $1.3M | Cash | RESEARCH/SUBCONTRACT |
JOHNS HOPKINS UNIVERSITY52-0595110 | BALTIMORE, MD | $1.3M | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL79-7926032 | DALLAS, TX | $1.3M | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO94-6036493 | SAN FRANCISCO, CA | $1.2M | Cash | RESEARCH/SUBCONTRACT |
SAGE BIONETWORKS26-4489946 | SEATTLE, WA | $1.1M | Cash | RESEARCH/SUBCONTRACT |
BOCA RATON REGIONAL HOSPITAL INC59-1006663 | BOCA RATON, FL | $986.2K | Cash | RESEARCH/SUBCONTRACT |
NEW YORK UNIVERSITY13-5562308 | NEW YORK, NY | $967K | Cash | RESEARCH/SUBCONTRACT |
MEDICAL UNIVERSITY OF SOUTH CAROLINA57-6000722 | CHARLESTON, SC | $959.3K | Cash | RESEARCH/SUBCONTRACT |
WASHINGTON UNIVERSITY43-0653611 | ST LOUIS, MO | $942.3K | Cash | RESEARCH/SUBCONTRACT |
THE TASK FORCE FOR GLOBAL HEALTH INC58-1698648 | DECATUR, GA | $918.8K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY PHYSCIANS INCORPORATED74-2161737 | AURORA, CO | $917.6K | Cash | RESEARCH/SUBCONTRACT |
| NEW YORK, NY | $891.6K | Cash | RESEARCH/SUBCONTRACT | |
CASE WESTERN RESERVE UNIVERSITY34-1018992 | CLEVELAND, OH | $873.6K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF TENNESSEE62-6001636 | KNOXVILLE, TN | $834.7K | Cash | RESEARCH/SUBCONTRACT |
THE JACKSON LABORATORY | BAR HARBOR, ME | $800.4K | Cash | RESEARCH/SUBCONTRACT |
| DECATUR, GA | $795K | Cash | RESEARCH/SUBCONTRACT | |
WEILL CORNELL MEDICAL COLLEGE13-1623978 | NEW YORK, NY | $778.1K | Cash | RESEARCH/SUBCONTRACT |
SPRINGBOARD HEALTHLAB87-1818608 | RICHMOND, CA | $712.2K | Cash | RESEARCH/SUBCONTRACT |
THE OHIO STATE UNIVERSITY31-6025986 | COLUMBUS, OH | $708.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF CHICAGO36-2177139 | CHICAGO, IL | $671.1K | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF TEXAS AT AUSTIN74-6000203 | AUSTIN, TX | $642.5K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO94-1539563 | LA JOLLA, CA | $633K | Cash | RESEARCH/SUBCONTRACT |
CALIFORNIA INSTITUTE OF TECHNOLOGY95-1643307 | PASADENA, CA | $596.6K | Cash | RESEARCH/SUBCONTRACT |
ARIDIS PHARMACEUTICALS INC47-2641188 | LOS GATOS, CA | $594.9K | Cash | RESEARCH/SUBCONTRACT |
NORTHWESTERN UNIVERSITY36-2167817 | EVANSTON, IL | $565.5K | Cash | RESEARCH/SUBCONTRACT |
SEATTLE CHILDREN'S HOSPITAL91-0564748 | SEATTLE, WA | $563.2K | Cash | RESEARCH/SUBCONTRACT |
VANDERBILT UNIVERSITY62-0476822 | NASHVILLE, TN | $559K | Cash | RESEARCH/SUBCONTRACT |
BRIGHAM AND WOMENS HOSPITAL INC | BOSTON, MA | $537.2K | Cash | RESEARCH/SUBCONTRACT |
TRUSTEES OF BOSTON UNIVERSITY | BOSTON, MA | $531.5K | Cash | RESEARCH/SUBCONTRACT |
NATIONWIDE CHILDREN'S HOSPITAL31-4379441 | COLUMBUS, OH | $514.3K | Cash | RESEARCH/SUBCONTRACT |
| AUGUSTA, GA | $498.5K | Cash | RESEARCH/SUBCONTRACT | |
CORNELL UNIVERSITY15-0532082 | ITHACA, NY | $475.2K | Cash | RESEARCH/SUBCONTRACT |
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA73-1563627 | OKLAHOMA CITY, OK | $463.3K | Cash | RESEARCH/SUBCONTRACT |
SIGNAL GROUP CONSULTING LLC71-0870873 | WASHINGTON, DC | $461K | Cash | RESEARCH/SUBCONTRACT |
BROWN UNIVERSITY OF PROVIDENCE | PROVIDENCE, RI | $451.7K | Cash | RESEARCH/SUBCONTRACT |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY | CAMBRIDGE, MA | $449.7K | Cash | RESEARCH/SUBCONTRACT |
MAYO CLINIC JACKSONVILLE59-3337028 | ROCHESTER, MN | $444.2K | Cash | RESEARCH/SUBCONTRACT |
GEORGIA COUNCIL FOR RECOVERY INC58-2045112 | ATLANTA, GA | $440.4K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF LOUISIANA LAFAYETTE72-6000820 | LAFAYETTE, LA | $422.2K | Cash | RESEARCH/SUBCONTRACT |
ALBERT EINSTEIN COLLEGE OF MEDICINE83-0621846 | BRONX, NY | $411K | Cash | RESEARCH/SUBCONTRACT |
AUGUSTA UNIVERSITY58-6002053 | AUGUSTA, GA | $408.6K | Cash | RESEARCH/SUBCONTRACT |
GEORGE WASHINGTON UNIVERSITY53-0196584 | WASHINGTON, DC | $397.7K | Cash | RESEARCH/SUBCONTRACT |
| LOUISVILLE, KY | $397.7K | Cash | RESEARCH/SUBCONTRACT | |
BAYLOR COLLEGE OF MEDICINE74-1613878 | HOUSTON, TX | $386.7K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF MIAMI59-0624458 | CORAL GABLES, FL | $373.3K | Cash | RESEARCH/SUBCONTRACT |
TRUSTEES OF DARTMOUTH COLLEGE | HANOVER, NH | $369.4K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF UTAH87-6000525 | SALT LAKE CITY, UT | $368.3K | Cash | RESEARCH/SUBCONTRACT |
WAYNE STATE UNIVERSITY38-6028429 | DETROIT, MI | $365.6K | Cash | RESEARCH/SUBCONTRACT |
COVARSADX CORP88-3778686 | DOWNEY, CA | $365.1K | Cash | RESEARCH/SUBCONTRACT |
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION88-6000024 | RENO, NV | $359.5K | Cash | RESEARCH/SUBCONTRACT |
CHILDREN'S HOSPITAL MEDICAL CENTER31-0833936 | CINCINNATI, OH | $339.6K | Cash | RESEARCH/SUBCONTRACT |
THE CHILDREN'S HOSPITAL OF PHILADELPHIA23-1352166 | PHILADELPHIA, PA | $338.6K | Cash | RESEARCH/SUBCONTRACT |
RUSH UNIVERSITY MEDICAL CENTER36-2174823 | CHICAGO, IL | $336.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON74-1761309 | DALLAS, TX | $336.2K | Cash | RESEARCH/SUBCONTRACT |
| TAMPA, FL | $334.6K | Cash | RESEARCH/SUBCONTRACT | |
VANDERBILT UNIVERSITY MEDICAL CENTER35-2528741 | NASHVILLE, TN | $333.5K | Cash | RESEARCH/SUBCONTRACT |
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY54-6001805 | BLACKSBURG, VA | $330.3K | Cash | RESEARCH/SUBCONTRACT |
NEIGHBORS BUILDING NEIGHBORHOODS OF MUSKOGEE INC73-1600003 | MUSKOGEE, OK | $328.5K | Cash | RESEARCH/SUBCONTRACT |
| CHARLOTTESVILLE, VA | $325.8K | Cash | RESEARCH/SUBCONTRACT | |
PRESIDENT AND FELLOWS OF HARVARD COLLEGE | BOSTON, MA | $315K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT BERKELEY94-6002123 | BERKELEY, CA | $310.1K | Cash | RESEARCH/SUBCONTRACT |
PHOEBE PHYSICIAN GROUP INC26-3792403 | ALBANY, GA | $310K | Cash | RESEARCH/SUBCONTRACT |
GENEVA FOUNDATION91-1593913 | TACOMA, WA | $305.4K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF SOUTHERN CALIFORNIA95-1642394 | LOS ANGELES, CA | $299.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF OREGON46-4727800 | EUGENE, OR | $296.5K | Cash | RESEARCH/SUBCONTRACT |
ST JUDE CHILDREN'S RESEARCH HOSPITAL INC62-0646012 | MEMPHIS, TN | $283K | Cash | RESEARCH/SUBCONTRACT |
| PISCATAWAY, NJ | $279.4K | Cash | RESEARCH/SUBCONTRACT | |
UNIVERSITY OF CINCINNATI31-6000989 | CINCINNATI, OH | $271.4K | Cash | RESEARCH/SUBCONTRACT |
OREGON HEALTH & SCIENCE UNIVERSITY93-1176109 | PORTLAND, OR | $271K | Cash | RESEARCH/SUBCONTRACT |
NORTHEAST GEORGIA PHYSICIANS GROUP INC58-2078064 | GAINESVILLE, GA | $260K | Cash | RESEARCH/SUBCONTRACT |
AMERICAN CANCER SOCIETY INC13-1788491 | KENNESAW, DC | $256.6K | Cash | Grant/Sponsorship |
THE UNIVERSITY OF MASSACHUSETTS | WORCESTER, MA | $255.6K | Cash | RESEARCH/SUBCONTRACT |
THE MIRIAM HOSPITAL | PROVIDENCE, RI | $254.6K | Cash | RESEARCH/SUBCONTRACT |
DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $253.6K | Cash | RESEARCH/SUBCONTRACT |
LA JOLLA INSTITUTE OF IMMUNOLOGY33-0328688 | LA JOLLA, CA | $253K | Cash | RESEARCH/SUBCONTRACT |
MEDICAL CENTER OF CENTRAL GEORGIA INC58-2149128 | MACON, GA | $251.1K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF SOUTH FLORIDA59-3102112 | TAMPA, FL | $248.2K | Cash | RESEARCH/SUBCONTRACT |
CEDARS-SINAI MEDICAL CENTER95-1644600 | LOS ANGELES, CA | $244.3K | Cash | RESEARCH/SUBCONTRACT |
OLON USA LLC82-1583049 | CONCORD, OH | $242K | Cash | RESEARCH/SUBCONTRACT |
UTAH STATE UNIVERSITY87-6000528 | LOGAN, UT | $241.9K | Cash | RESEARCH/SUBCONTRACT |
SAVANNAH NEUROLOGY SPECIALISTS PC26-4598467 | SAVANNAH, GA | $237.3K | Cash | RESEARCH/SUBCONTRACT |
| BETHESDA, MD | $234.9K | Cash | RESEARCH/SUBCONTRACT | |
VAN ANDEL RESEARCH INSTITUTE52-2000823 | GRAND RAPIDS, MI | $230.6K | Cash | RESEARCH/SUBCONTRACT |
| ALBANY, NY | $224.9K | Cash | RESEARCH/SUBCONTRACT | |
UNIVERSITY OF ROCHESTER16-0743209 | ROCHESTER, NY | $222.6K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF TEXAS74-1761309 | AUSTIN, TX | $218.9K | Cash | RESEARCH/SUBCONTRACT |
SISTERLOVE INC58-2016070 | ATLANTA, GA | $218.6K | Cash | RESEARCH/SUBCONTRACT |
NATIONAL ALLIANCE OF STATE AND TERRITORIAL AIDS DIRECTORS91-1568650 | WASHINGTON, DC | $215.8K | Cash | RESEARCH/SUBCONTRACT |
MD ANDERSON CANCER CENTER74-6001118 | HOUSTON, TX | $215.4K | Cash | RESEARCH/SUBCONTRACT |
THE PENNSYLVANIA STATE UNIVERSITY24-6000376 | UNIVERSITY PARK, PA | $215.3K | Cash | RESEARCH/SUBCONTRACT |
COLORADO STATE UNIVERSITY84-6000545 | FORT COLLINS, CO | $211.1K | Cash | RESEARCH/SUBCONTRACT |
THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM39-1805963 | MADISON, WI | $209.5K | Cash | RESEARCH/SUBCONTRACT |
KITWARE INC14-1802694 | CLIFTON PARK, NY | $209.1K | Cash | RESEARCH/SUBCONTRACT |
| URBANA, IL | $208.1K | Cash | RESEARCH/SUBCONTRACT | |
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES95-2160097 | LA JOLLA, CA | $206.7K | Cash | RESEARCH/SUBCONTRACT |
THE BROAD INSTITUTE INC26-3428781 | CAMBRIDGE, MA | $204.3K | Cash | RESEARCH/SUBCONTRACT |
CHILDREN'S HOSPITAL CORPORATION | BOSTON, MA | $204.2K | Cash | RESEARCH/SUBCONTRACT |
FARMWORKER ASSOCIATION OF FLORIDA INC59-2683978 | APOPKA, FL | $202.4K | Cash | RESEARCH/SUBCONTRACT |
AU MEDICAL CENTER INC58-2144788 | AUGUSTA, GA | $201.1K | Cash | RESEARCH/SUBCONTRACT |
| ORLANDO, FL | $200K | Cash | GRANT | |
WESTAT INC84-0529566 | ROCKVILLE, MD | $194.9K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF NEW MEXICO85-6000642 | ALBUQUERQUE, NM | $186.4K | Cash | RESEARCH/SUBCONTRACT |
| ATLANTA, GA | $183.1K | Cash | RESEARCH/SUBCONTRACT | |
LSU HEALTH SCIENCES CTR-NEW ORLEANS72-6087770 | NEW ORLEANS, LA | $180.8K | Cash | RESEARCH/SUBCONTRACT |
TEXAS BIOMEDICAL RESEARCH INSTITUTE74-1109630 | SAN ANTONIO, TX | $178.3K | Cash | RESEARCH/SUBCONTRACT |
CHILDRENS RESEARCH INSTITUTE52-1654453 | WASHINGTON, DC | $178.3K | Cash | RESEARCH/SUBCONTRACT |
MERCER UNIVERSITY58-0566167 | MACON, GA | $173K | Cash | RESEARCH/SUBCONTRACT |
LSU HEALTH SCIENCES CTR-SHREVEPORT72-0702002 | SHREVEPORT, LA | $172.7K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF IOWA42-6004813 | IOWA CITY, IA | $167.2K | Cash | RESEARCH/SUBCONTRACT |
WILLIAM MARCH RICE UNIVERSITY74-1109620 | HOUSTON, TX | $166.5K | Cash | RESEARCH/SUBCONTRACT |
DENVER HEALTH & HOSPITAL AUTHORITY84-1343242 | DENVER, CO | $161.9K | Cash | RESEARCH/SUBCONTRACT |
KLEIN BUENDEL INC84-1612798 | GOLDEN, CO | $155.8K | Cash | RESEARCH/SUBCONTRACT |
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON91-0653422 | SEATTLE, WA | $150K | Cash | RESEARCH/SUBCONTRACT |
FEMINIST WOMEN'S HEALTH CENTER INC58-1273243 | ATLANTA, GA | $150K | Cash | Research/Subcontract |
INOTIV INC35-1345024 | WEST LAFAYETTE, IN | $138.1K | Cash | RESEARCH/SUBCONTRACT |
INDIANA UNIVERSITY35-6001673 | BLOOMINGTON, IN | $137.8K | Cash | RESEARCH/SUBCONTRACT |
LOVELACE BIOMEDICAL RESEARCH INSTITUTE85-0110669 | ALBUQUERQUE, NM | $137.2K | Cash | RESEARCH/SUBCONTRACT |
ENVIRONMENTAL COMMUNITY ACTION INC58-1854834 | ATLANTA, GA | $135.8K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES95-6006143 | LOS ANGELES, CA | $135.5K | Cash | RESEARCH/SUBCONTRACT |
THE MASSACHUSETTS GENERAL HOSPITAL | SOMERVILLE, MA | $135.4K | Cash | RESEARCH/SUBCONTRACT |
| NEW YORK, NY | $128K | Cash | RESEARCH/SUBCONTRACT | |
GREAT PLAINS TRIBAL LEADERS HEALTH BOARD46-0420063 | RAPID CITY, SD | $127.7K | Cash | RESEARCH/SUBCONTRACT |
SIEMENS MEDICAL SOLUTIONS USA22-2417778 | PRINCETON, NJ | $126.1K | Cash | RESEARCH/SUBCONTRACT |
CHILDREN'S ENVIRONMENTAL HEALTH NETWORK52-2305620 | WASHINGTON, DC | $122.4K | Cash | RESEARCH/SUBCONTRACT |
MERIDIAN EDUCATION RESOURCE GROUP INC58-2180056 | ATLANTA, GA | $121.5K | Cash | RESEARCH/SUBCONTRACT |
TRUSTEES OF PRINCETON UNIVERSITY21-0634501 | PRINCETON, NJ | $115.3K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA94-6036494 | DAVIS, CA | $112.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF SOUTH CAROLINA57-6001153 | COLUMBIA, SC | $112.1K | Cash | RESEARCH/SUBCONTRACT |
PROVIDENCE SACRED HEART MEDICAL CENTER36-4640211 | SPOKANE, WA | $111.9K | Cash | RESEARCH/SUBCONTRACT |
ARIZONA STATE UNIVERSITY86-0196696 | TEMPE, AZ | $110.4K | Cash | RESEARCH/SUBCONTRACT |
WUQU KAWOQ SA20-8741625 | BETHEL, VT | $109K | Cash | RESEARCH/SUBCONTRACT |
SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION95-6042721 | SAN DIEGO, CA | $106.8K | Cash | RESEARCH/SUBCONTRACT |
RUTGERS HEALTH GROUP INC81-3423110 | NEW BRUNSWICK, NJ | $105K | Cash | RESEARCH/SUBCONTRACT |
| AUGUSTA, GA | $104.7K | Cash | RESEARCH/SUBCONTRACT | |
UNIVERSITY OF GEORGIA58-6001998 | ATLANTA, GA | $104.6K | Cash | RESEARCH/SUBCONTRACT |
| PHILADELPHIA, PA | $100.2K | Cash | RESEARCH/SUBCONTRACT | |
VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO13-3018939 | SAN DIEGO, CA | $90.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | BURLINGTON, VT | $89.4K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY CORPORATION FOR ATMOSPHERIC84-0412668 | BOULDER, CO | $88K | Cash | RESEARCH/SUBCONTRACT |
THE SCRIPPS RESEARCH INSTITUTE33-0435954 | LA JOLLA, CA | $87.6K | Cash | RESEARCH/SUBCONTRACT |
| CHICAGO, IL | $87.4K | Cash | RESEARCH/SUBCONTRACT | |
CHILDRENS HOSPITAL LOS ANGELES95-1690977 | LOS ANGELES, CA | $87.3K | Cash | RESEARCH/SUBCONTRACT |
WAKE FOREST UNIVERSITY HEALTH SCIENCES22-3849199 | WINSTONSALEM, NC | $86.4K | Cash | RESEARCH/SUBCONTRACT |
BIENESTAR HUMAN SERVICES INC95-4505737 | LOS ANGELES, CA | $86.4K | Cash | RESEARCH/SUBCONTRACT |
INTER TRIBAL COUNCIL OF MICHIGAN INC38-1893519 | SAULT STE MARIE, MI | $86K | Cash | RESEARCH/SUBCONTRACT |
ST LOUIS UNIVERSITY43-0654872 | ST LOUIS, MO | $84.1K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF KANSAS48-1124839 | KANSAS CITY, KS | $83.6K | Cash | RESEARCH/SUBCONTRACT |
THE MEDICAL COLLEGE OF WISCONSIN INC39-0806261 | MILWAUKEE, WI | $82.6K | Cash | RESEARCH/SUBCONTRACT |
| NEW ORLEANS, LA | $81.4K | Cash | RESEARCH/SUBCONTRACT | |
GEORGIA DEPARTMENT OF PUBLIC HEALTH90-0676388 | ATLANTA, GA | $76.9K | Cash | RESEARCH/SUBCONTRACT |
REGENSTRIEF INSTITUTE INC30-0007730 | INDIANAPOLIS, IN | $75.8K | Cash | RESEARCH/SUBCONTRACT |
OHIO UNIVERSITY31-6402113 | ATHENS, OH | $75.2K | Cash | RESEARCH/SUBCONTRACT |
RHODE ISLAND HOSPITAL | PROVIDENCE, RI | $74.5K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION61-6033693 | LEXINGTON, KY | $73.9K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF CONNECTICUT HEALTH CENTER52-1725543 | FARMINGTON, CT | $73.6K | Cash | RESEARCH/SUBCONTRACT |
RESUSCITATION ACADEMY FOUNDATION81-2193189 | SEATTLE, WA | $72.9K | Cash | RESEARCH/SUBCONTRACT |
SHEPHERD CENTER INC51-0141601 | ATLANTA, GA | $72.1K | Cash | RESEARCH/SUBCONTRACT |
CARNEGIE MELLON UNIVERSITY25-0969449 | PITTSBURGH, PA | $71.3K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF MONTANA81-6001713 | MISSOULA, MT | $69.3K | Cash | RESEARCH/SUBCONTRACT |
OREGON STATE UNIVERSITY61-1730890 | CORVALLIS, OR | $69K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF PUERTO RICO66-0433762 | SAN JUAN, PR | $69K | Cash | RESEARCH/SUBCONTRACT |
PRIMORDIA BIOSYSTEMS INC85-3933848 | COSTA MESA, CA | $68.7K | Cash | RESEARCH/SUBCONTRACT |
THE RAND CORPORATION95-1958142 | SANTA MONICA, CA | $67.2K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF COLORADO84-6000555 | DENVER, CO | $67.2K | Cash | RESEARCH/SUBCONTRACT |
CLARK ATLANTA UNIVERSITY INC58-1825259 | ATLANTA, GA | $66.6K | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES71-6046242 | LITTLE ROCK, AR | $65.7K | Cash | RESEARCH/SUBCONTRACT |
DARTMOUTH HITCHCOCK22-2519596 | LEBANON, NH | $62.5K | Cash | RESEARCH/SUBCONTRACT |
MEMORIAL SLOAN-KETTERING CANCER CENTER13-1924236 | NEW YORK, NY | $61.5K | Cash | RESEARCH/SUBCONTRACT |
VETERANS HEALTH ADMINISTRATION91-0565166 | SEATTLE, WA | $59.9K | Cash | RESEARCH/SUBCONTRACT |
GEORGIA STATE UNIVERSITY58-6002050 | ATLANTA, GA | $59.8K | Cash | RESEARCH/SUBCONTRACT |
NORTH CAROLINA STATE UNIVERSITY56-6000756 | RALEIGH, NC | $59K | Cash | RESEARCH/SUBCONTRACT |
WESTERN WASHINGTON UNIVERSITY91-6000562 | BELLINGHAM, WA | $58.4K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF ARKANSAS71-0236904 | FAYETTEVILLE, AR | $58K | Cash | RESEARCH/SUBCONTRACT |
THOMAS JEFFERSON UNIVERSITY23-1352651 | PHILADELPHIA, PA | $56.8K | Cash | RESEARCH/SUBCONTRACT |
STETHX MICROSYSTEMS INC83-1416475 | ATLANTA, GA | $56.8K | Cash | RESEARCH/SUBCONTRACT |
VIRGINIA COMMONWEALTH UNIVERSITY54-6001758 | RICHMOND, VA | $55.8K | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF TEXAS AT SAN ANTONIO74-1717115 | SAN ANTONIO, TX | $55.2K | Cash | RESEARCH/SUBCONTRACT |
HEALTH THROUGH WALLS INC55-0909719 | NORTH MIAMI, FL | $55K | Cash | Research/Subcontract |
HARVARD PILGRIM HEALTH CARE INC | CANTON, MA | $54.9K | Cash | RESEARCH/SUBCONTRACT |
MEDSHARE INTERNATIONAL INC58-2433968 | Atlanta, GA | $54.3K | Non-Cash | MEDICAL SUPPLIES |
GEORGE MASON UNIVERSITY54-0836354 | FAIRFAX, VA | $54.1K | Cash | RESEARCH/SUBCONTRACT |
CALIFORNIA STATE UNIVERSITY LONG BEACH RESEARCH FOUNDATION95-6106694 | LONG BEACH, CA | $52.7K | Cash | RESEARCH/SUBCONTRACT |
CHEROKEE NATION73-0757033 | TAHLEQUAH, OK | $52.6K | Cash | RESEARCH/SUBCONTRACT |
| LA JOLLA, CA | $52K | Cash | RESEARCH/SUBCONTRACT | |
SYNEOS HEALTH LLC33-0723120 | BOSTON, MA | $50.9K | Cash | RESEARCH/SUBCONTRACT |
CLEAR ANALYTICS84-4341820 | BOWIE, MD | $50.4K | Cash | RESEARCH/SUBCONTRACT |
THE CLEVELAND CLINIC FOUNDATION34-0714585 | INDEPENDENCE, OH | $49.8K | Cash | RESEARCH/SUBCONTRACT |
WAKE FOREST UNIVERSITY56-0532138 | WINSTONSALEM, NC | $49.6K | Cash | RESEARCH/SUBCONTRACT |
TUFTS MEDICAL CENTER INC | BOSTON, MA | $49.3K | Cash | RESEARCH/SUBCONTRACT |
| TUCKER, GA | $48.3K | Cash | RESEARCH/SUBCONTRACT | |
ECOGNOSIS LLC92-0725456 | WARWICK, RI | $46.2K | Cash | Research/Subcontract |
GEORGIA POLST COLLABORATIVE81-5422799 | STOCKBRIDGE, GA | $42.5K | Cash | GRANT |
THE MCLEAN HOSPITAL CORPORATION | SOMERVILLE, MA | $42.3K | Cash | RESEARCH/SUBCONTRACT |
STONY BROOK FOUNDATION INC11-6077945 | STONY BROOK, NY | $42K | Cash | RESEARCH/SUBCONTRACT |
CEREBRAL PALSY FOUNDATION INC13-6093337 | NEW YORK, NY | $40K | Cash | Research/Subcontract |
THE GRADY HEALTH FOUNDATION INC58-2130437 | ATLANTA, GA | $40K | Cash | Grant/Sponsorship |
ALLEN INSTITUTE91-2155317 | SEATTLE, WA | $39K | Cash | RESEARCH/SUBCONTRACT |
LEHIGH UNIVERSITY24-0795445 | BETHLEHEM, PA | $38.6K | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT SAN DIEGO95-6006144 | LA JOLLA, CA | $38.6K | Cash | RESEARCH/SUBCONTRACT |
DREXEL UNIVERSITY23-1352630 | PHILADELPHIA, PA | $38.4K | Cash | RESEARCH/SUBCONTRACT |
BOISE STATE UNIVERSITY82-0290701 | BOISE, ID | $38.4K | Cash | RESEARCH/SUBCONTRACT |
LOUISIANA STATE UNIVERSITY AND A&M COLLEGE72-6000848 | BATON ROUGE, LA | $37.8K | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIA74-1586031 | SAN ANTONIO, TX | $37.3K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF NORTH CAROLINA GREENSBORO56-6001468 | GREENSBORO, NC | $37.1K | Cash | RESEARCH/SUBCONTRACT |
AMERICAN ACADEMY OF NURSING52-2213870 | WASHINGTON, NY | $36.5K | Cash | Grant/Sponsorship |
NAESM INC58-1986941 | ATLANTA, GA | $35.6K | Cash | RESEARCH/SUBCONTRACT |
FAMILIES FIRST INC58-1054331 | ATLANTA, GA | $35.3K | Cash | RESEARCH/SUBCONTRACT |
| ATLANTA, GA | $34.1K | Cash | RESEARCH/SUBCONTRACT | |
CRYOUT TEEN ORGANIZATION46-0658562 | TERRY, MS | $33.8K | Cash | Subcontract |
PURDUE UNIVERSITY35-6002041 | WEST LAFAYETTE, IN | $33K | Cash | RESEARCH/SUBCONTRACT |
PUBLIC HEALTH INSTITUTE94-1646278 | OAKLAND, CA | $32.7K | Cash | RESEARCH/SUBCONTRACT |
SPELMAN COLLEGE58-0566243 | ATLANTA, GA | $32.2K | Cash | RESEARCH/SUBCONTRACT |
VITALANT86-0098929 | SCOTTSDALE, AZ | $31.8K | Cash | RESEARCH/SUBCONTRACT |
| PORTLAND, OR | $31.1K | Cash | RESEARCH/SUBCONTRACT | |
BELMAR PHARMACY20-4611466 | GOLDEN, CO | $30.6K | Cash | RESEARCH/SUBCONTRACT |
STATE UNIVERSITY OF NEW YORK14-6013200 | ALBANY, NY | $30.6K | Cash | RESEARCH/SUBCONTRACT |
LAGRANGE COLLEGE58-0566199 | LAGRANGE, GA | $30K | Cash | Research/Subcontract |
THE NORTHSIDE HOSPITAL FOUNDATION INC58-1653541 | ATLANTA, GA | $29.9K | Cash | RESEARCH/SUBCONTRACT |
THE POPULATION COUNCIL INC13-1687001 | NEW YORK, NY | $29.2K | Cash | RESEARCH/SUBCONTRACT |
ALBANY AREA PRIMARY HEALTH CARE INC58-1344015 | ALBANY, GA | $29K | Cash | RESEARCH/SUBCONTRACT |
TEXAS TECH UNIVERSITY75-6002622 | LUBBOCK, TX | $28.9K | Cash | RESEARCH/SUBCONTRACT |
THE ACCESS TO ADVANCED HEALTH INSTITUTE91-1608978 | SEATTLE, WA | $28.2K | Cash | RESEARCH/SUBCONTRACT |
NATIONAL JEWISH HEALTH74-2044647 | DENVER, CO | $27K | Cash | RESEARCH/SUBCONTRACT |
GEORGETOWN UNIVERSITY53-0196603 | WASHINGTON, DC | $26.2K | Cash | RESEARCH/SUBCONTRACT |
ATLANTA METROPOLITAN STATE COLLEGE58-1190222 | ATLANTA, GA | $25.6K | Cash | RESEARCH/SUBCONTRACT |
J CRAIG VENTER INSTITUTE INC52-1842938 | LA JOLLA, CA | $25.3K | Cash | RESEARCH/SUBCONTRACT |
RESEARCH AMERICA52-1609875 | Arlington, GA | $25K | Cash | Grant/Sponsorship |
WABE FOUNDATION INC84-3475573 | Atlanta, NY | $25K | Cash | Grant/Sponsorship |
INSCOPIX INC27-3632371 | MOUNTAIN VIEW, CA | $24.8K | Cash | RESEARCH/SUBCONTRACT |
THE MEDICAL CENTER INC58-1685139 | COLUMBUS, GA | $24.7K | Cash | RESEARCH/SUBCONTRACT |
HEALTH RESEARCH INCORPORATED14-1402155 | MENANDS, NY | $23.8K | Cash | RESEARCH/SUBCONTRACT |
TRUSTEES OF TUFTS COLLEGE | BOSTON, MA | $23.1K | Cash | RESEARCH/SUBCONTRACT |
ZABBIO INC82-2969965 | SAN DIEGO, CA | $22.5K | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF ARIZONA74-2652689 | TUCSON, AZ | $22.5K | Cash | RESEARCH/SUBCONTRACT |
PEROSPHERE TECHNOLOGIES INC82-2428045 | DANBURY, CT | $21.5K | Cash | RESEARCH/SUBCONTRACT |
EAST TENNESSEE STATE UNIVERSITY62-6021046 | JOHNSON CITY, TN | $21.1K | Cash | RESEARCH/SUBCONTRACT |
CLEMSON UNIVERSITY57-6000254 | CLEMSON, SC | $20.9K | Cash | Subcontract |
SANFORD RESEARCH46-0450378 | SIOUX FALLS, SD | $20.3K | Cash | RESEARCH/SUBCONTRACT |
EAST GEORGIA HEALTHCARE CENTER INC58-2001607 | SWAINSBORO, GA | $20K | Cash | RESEARCH/SUBCONTRACT |
HEALTH CONNECT SOUTH INC46-3967515 | Smyrna, MA | $20K | Cash | Grant/Sponsorship |
HILL FIRST BAPTIST CHURCH35-2424558 | ATHENS, GA | $20K | Cash | Grants/Sponsorship |
RALLY FOUNDATION INC20-1950849 | ATLANTA, GA | $20K | Cash | Grant/Sponsorship |
ST LUKE LUTHERAN CHURCH OF ATLANTA59-1153406 | Atlanta, GA | $20K | Cash | Grants/Sponsorship |
CANDLER HOSPITAL INCORPORATED58-0593388 | SAVANNAH, GA | $19.9K | Cash | RESEARCH/SUBCONTRACT |
MICHIGAN STATE UNIVERSITY38-6005984 | EAST LANSING, MI | $19.2K | Cash | RESEARCH/SUBCONTRACT |
NORTHEASTERN UNIVERSITY | BOSTON, MA | $19K | Cash | RESEARCH/SUBCONTRACT |
FLORIDA STATE UNIVERSITY59-1961248 | TALLAHASSEE, FL | $18.9K | Cash | RESEARCH/SUBCONTRACT |
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER64-6008520 | JACKSON, MS | $17.5K | Cash | RESEARCH/SUBCONTRACT |
BETH ISRAEL DEACONESS MEDICAL CENTER INC | BOSTON, MA | $17.2K | Cash | RESEARCH/SUBCONTRACT |
AMERICAN NURSES ASSOCIATION13-1893923 | SILVER SPRING, MD | $17.2K | Cash | RESEARCH/SUBCONTRACT |
AMERICAN UNIVERSITY53-0196549 | WASHINGTON, DC | $16.7K | Cash | RESEARCH/SUBCONTRACT |
| NEW YORK, NY | $16.3K | Cash | RESEARCH/SUBCONTRACT | |
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE95-6006142 | RIVERSIDE, CA | $16.3K | Cash | RESEARCH/SUBCONTRACT |
AID ATLANTA INC58-1537967 | ATLANTA, GA | $16.2K | Cash | GRANT |
GEORGIA HARM REDUCTION COALITION INC58-2227958 | ATLANTA, GA | $16.2K | Cash | GRANT |
| CHICAGO, IL | $15.8K | Cash | RESEARCH/SUBCONTRACT | |
KENNEDY KRIEGER CHILDRENS HOSPITAL INC52-0607971 | BALTIMORE, MD | $15.8K | Cash | RESEARCH/SUBCONTRACT |
HORIZONS COMMUNITY SOLUTIONS INC82-0567901 | ALBANY, GA | $15.3K | Cash | RESEARCH/SUBCONTRACT |
ADVOCATE HEALTH & HOSP CORP36-2169147 | DOWNERS GROVE, IL | $15K | Cash | GRANT |
DAUGHTERS AGAINST ALZHEIMERS INC83-1484206 | Atlanta, GA | $15K | Cash | Grant/Sponsorship |
INFORMED HORIZONS EDUCATION INC83-2375324 | TUCKER, GA | $15K | Cash | Grant/Sponsorship |
NATIONAL ASSOCIATION OF HISPANIC NURSES INC91-1010677 | LEXINGTON, IL | $15K | Cash | Grant/Sponsorship |
AMERICAN COLLEGE OF RADIOLOGY36-2261602 | RESTON, VA | $14.4K | Cash | RESEARCH/SUBCONTRACT |
COLQUITT COUNTY BOH - ELLENTON FARMWORKER CLINIC58-6000356 | ALBANY, GA | $14.4K | Cash | RESEARCH/SUBCONTRACT |
MICHIGAN PUBLIC HEALTH INSTITUTE38-2963835 | OKEMOS, MI | $13.8K | Cash | RESEARCH/SUBCONTRACT |
HAWTHORNE SPATIAL LLC88-0749332 | SAINT PAUL, MN | $13.7K | Cash | RESEARCH/SUBCONTRACT |
| AKRON, OH | $13K | Cash | RESEARCH/SUBCONTRACT | |
| Atlanta, VA | $12.5K | Cash | Grant/Sponsorship | |
GEORGIA TRANSPLANT FOUNDATION58-2075193 | Roswell, GA | $12.5K | Cash | Grant/Sponsorship |
PIEDMONT HEALTHCARE INC58-1503902 | ATLANTA, GA | $12.4K | Cash | RESEARCH/SUBCONTRACT |
| GULF BREEZE, FL | $12.1K | Cash | RESEARCH/SUBCONTRACT | |
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER75-2668014 | LUBBOCK, TX | $11.5K | Cash | RESEARCH/SUBCONTRACT |
AIDS FOUNDATION HOUSTON INC76-0073661 | HOUSTON, TX | $10K | Cash | GRANT |
ANTI-DEFAMATION LEAGUE13-1818723 | NEW YORK, NY | $10K | Cash | Grant/Sponsorship |
DECATUR BOOK FESTIVAL INC20-8669575 | DECATUR, GA | $10K | Cash | GRANT |
FRIENDS FOR LIFE CORPORATION62-1511959 | MEMPHIS, TN | $10K | Cash | GRANT |
GEORGIA DEPT OF NATURAL RESOURCES58-1130945 | Social Circle, GA | $10K | Cash | Grant/Sponsorship |
GEORGIA PUBLIC HEALTH ASSOCIATION INC58-1556077 | Griffin, GA | $10K | Cash | Grant/Sponsorship |
| ATLANTA, GA | $10K | Cash | Research/Subcontract | |
GREENLIGHT FUND INC20-0407083 | Boston, GA | $10K | Cash | Grant/Sponsorship |
| ATLANTA, GA | $10K | Cash | Sponsorship | |
HOUSE OF SERENITY INC47-3731609 | ATLANTA, GA | $10K | Cash | Research/Subcontract |
LATINO COMMISSION ON AIDS INC13-3629466 | NEW YORK, NY | $10K | Cash | Research/Subcontract |
NATIONAL BRAIN TUMOR SOCIETY INC | NEWTON, KY | $10K | Cash | Grant/Sponsorship |
NORTH CAROLINA AIDS ACTION NETWORK32-0323779 | DURHAM, NC | $10K | Cash | Research/Subcontract |
OPERATION HOPE INC95-4378084 | Atlanta, MA | $10K | Cash | Grant/Sponsorship |
OUT MY CLOSET INC47-3121843 | BELLEROSE, NY | $10K | Cash | GRANT |
PROVIDENCE HEALTH SYSTEM - SO CALIFORNIA51-0216589 | RENTON, WA | $10K | Cash | RESEARCH/SUBCONTRACT |
RAIN INC56-1825247 | CHARLOTTE, NC | $10K | Cash | GRANT |
| ATLANTA, GA | $10K | Cash | GRANT | |
THE MARFAN FOUNDATION INC52-1265361 | Port Washington, NY | $10K | Cash | Grant/Sponsorship |
THE POVERELLO CENTER INC65-0056218 | WILTON MANORS, FL | $10K | Cash | GRANT |
TRANSFORMATIONS YOUTH GROUP83-2753730 | KANSAS CITY, MO | $10K | Cash | GRANT |
TRUE COLORS THEATRE COMPANY | ATLANTA, GA | $10K | Cash | GRANT |
WE LOVE BUFORD HIGHWAY INC82-2154696 | ATLANTA, GA | $10K | Cash | GRANT |
| TAMPA, FL | $9,859 | Cash | RESEARCH/SUBCONTRACT | |
THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY56-0529945 | CHARLOTTE, NC | $9,600 | Cash | GRANT |
CHILDREN'S MERCY HOSPITAL44-0605373 | KANSAS CITY, MO | $9,518 | Cash | RESEARCH/SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE95-2226406 | IRVINE, CA | $8,475 | Cash | RESEARCH/SUBCONTRACT |
PARENTS AS TEACHERS NATIONAL CENTER INC43-1569124 | ST LOUIS, MO | $8,369 | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF MISSOURI43-6003859 | COLUMBIA, MO | $8,362 | Cash | RESEARCH/SUBCONTRACT |
THE NEMOURS FOUNDATION59-0634433 | JACKSONVILLE, FL | $8,244 | Cash | RESEARCH/SUBCONTRACT |
ALBANY MEDICAL COLLEGE14-1338310 | ALBANY, NY | $8,000 | Cash | GRANT |
ATLANTA PRESS CLUB INC58-0969761 | ATLANTA, GA | $8,000 | Cash | GRANT |
TJ MARTELL FOUNDATION51-0180178 | NASHVILLE, TN | $8,000 | Cash | Grants/Sponsorship |
GEORGIA PUBLIC LIBRARY SERVICE58-6002348 | ATLANTA, GA | $7,980 | Cash | GRANT |
HENRY FORD HEALTH SYSTEM38-1357020 | DETROIT, MI | $7,862 | Cash | RESEARCH/SUBCONTRACT |
NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION INC94-3084159 | SAN FRANCISCO, CA | $7,778 | Cash | RESEARCH/SUBCONTRACT |
MASS GENERAL BRIGHAM INCORPORATED | SOMERVILLE, MA | $7,338 | Cash | RESEARCH/SUBCONTRACT |
MEMORIAL HEALTH MEADOWS PHYSICIANS85-2824108 | VIDALIA, GA | $6,666 | Cash | RESEARCH/SUBCONTRACT |
THE UNIVERSITY OF TOLEDO34-6401483 | TOLEDO, OH | $6,303 | Cash | RESEARCH/SUBCONTRACT |
FOUNDATION OF WESLEY WOODS INC58-1543164 | Atlanta, GA | $6,000 | Cash | Grant/Sponsorship |
MCLAREN HEALTH CARE CORPORATION38-2397643 | GRAND BLANC, MI | $6,000 | Cash | RESEARCH/SUBCONTRACT |
MUSCULAR DYSTROPHY ASSOCIATION13-1665552 | Chicago, GA | $6,000 | Cash | Grant/Sponsorship |
| Atlanta, GA | $5,666 | Cash | Grant/Sponsorship | |
ARKANSAS BLACK GAY MENS FORM84-4309426 | LITTLE ROCK, AR | $5,500 | Cash | RESEARCH/SUBCONTRACT |
GEORGIA BOARD OF NURSING58-1130945 | Macon, GA | $5,337 | Cash | Grant/Sponsorship |
| Total | $240.2M | |||
Atlanta, GA
$35.5M
Atlanta, GA
$34.8M
ORASURE TECHNOLOGIES INC
PHILADELPHIA, PA
$11.1M
ATLANTA, GA
$9.6M
FRED HUTCHINSON CANCER CENTER
SEATTLE, WA
$7.9M
ATLANTA, GA
$6.5M
$4.9M
OKLAHOMA MEDICAL RESEARCH FOUNDATION
OKLAHOMA CITY, OK
$4.8M
DCN DIAGNOSTICS
CARLSBAD, CA
$4.7M
BETHESDA, MD
$4M
ATLANTA, GA
$4M
LINCOLN, NE
$3.7M
UNIVERSITY OF MARYLAND
COLLEGE PARK, MD
$3.4M
$3.3M
DURHAM, NC
$3.1M
YALE UNIVERSITY
NEW HAVEN, CT
$2.7M
ATLANTA, GA
$2.6M
UNIVERSITY OF WASHINGTON
SEATTLE, WA
$2.5M
PITTSBURGH, PA
$2.5M
$2.5M
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
REDWOOD CITY, CA
$2.3M
ANN ARBOR, MI
$2.3M
PHILADELPHIA, PA
$2.3M
THE GENERAL HOSPITAL CORPORATION
SOMERVILLE, MA
$2.2M
CENTERS FOR DISEASE CONTROL & PREVENTION
ATLANTA, GA
$2.1M
DURHAM, NC
$2.1M
WESTBURY, NY
$2M
CHAPEL HILL, NC
$1.9M
UNIVERSITY OF ALABAMA AT BIRMINGHAM
BIRMINGHAM, AL
$1.9M
REGENTS OF THE UNIVERSITY OF MINNESOTA
MINNEAPOLIS, MN
$1.8M
$1.4M
ATLANTA, GA
$1.4M
RHO FEDERAL SYSTEMS DIVISION INC
DURHAM, NC
$1.4M
GAINESVILLE, FL
$1.4M
NEW YORK, NY
$1.3M
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
GALVESTON, TX
$1.3M
KAISER FOUNDATION HOSPITALS
OAKLAND, CA
$1.3M
BALTIMORE, MD
$1.3M
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL
DALLAS, TX
$1.3M
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
SAN FRANCISCO, CA
$1.2M
SEATTLE, WA
$1.1M
BOCA RATON, FL
$986.2K
NEW YORK, NY
$967K
MEDICAL UNIVERSITY OF SOUTH CAROLINA
CHARLESTON, SC
$959.3K
ST LOUIS, MO
$942.3K
DECATUR, GA
$918.8K
UNIVERSITY PHYSCIANS INCORPORATED
AURORA, CO
$917.6K
NEW YORK, NY
$891.6K
CLEVELAND, OH
$873.6K
UNIVERSITY OF TENNESSEE
KNOXVILLE, TN
$834.7K
THE JACKSON LABORATORY
BAR HARBOR, ME
$800.4K
$795K
WEILL CORNELL MEDICAL COLLEGE
NEW YORK, NY
$778.1K
SPRINGBOARD HEALTHLAB
RICHMOND, CA
$712.2K
COLUMBUS, OH
$708.5K
CHICAGO, IL
$671.1K
THE UNIVERSITY OF TEXAS AT AUSTIN
AUSTIN, TX
$642.5K
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
LA JOLLA, CA
$633K
CALIFORNIA INSTITUTE OF TECHNOLOGY
PASADENA, CA
$596.6K
ARIDIS PHARMACEUTICALS INC
LOS GATOS, CA
$594.9K
EVANSTON, IL
$565.5K
SEATTLE CHILDREN'S HOSPITAL
SEATTLE, WA
$563.2K
NASHVILLE, TN
$559K
BRIGHAM AND WOMENS HOSPITAL INC
BOSTON, MA
$537.2K
TRUSTEES OF BOSTON UNIVERSITY
BOSTON, MA
$531.5K
COLUMBUS, OH
$514.3K
AUGUSTA, GA
$498.5K
ITHACA, NY
$475.2K
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
OKLAHOMA CITY, OK
$463.3K
SIGNAL GROUP CONSULTING LLC
WASHINGTON, DC
$461K
BROWN UNIVERSITY OF PROVIDENCE
PROVIDENCE, RI
$451.7K
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
CAMBRIDGE, MA
$449.7K
ROCHESTER, MN
$444.2K
ATLANTA, GA
$440.4K
UNIVERSITY OF LOUISIANA LAFAYETTE
LAFAYETTE, LA
$422.2K
BRONX, NY
$411K
AUGUSTA, GA
$408.6K
WASHINGTON, DC
$397.7K
LOUISVILLE, KY
$397.7K
BAYLOR COLLEGE OF MEDICINE
HOUSTON, TX
$386.7K
CORAL GABLES, FL
$373.3K
TRUSTEES OF DARTMOUTH COLLEGE
HANOVER, NH
$369.4K
UNIVERSITY OF UTAH
SALT LAKE CITY, UT
$368.3K
DETROIT, MI
$365.6K
COVARSADX CORP
DOWNEY, CA
$365.1K
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION
RENO, NV
$359.5K
CINCINNATI, OH
$339.6K
PHILADELPHIA, PA
$338.6K
CHICAGO, IL
$336.5K
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
DALLAS, TX
$336.2K
$334.6K
NASHVILLE, TN
$333.5K
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
BLACKSBURG, VA
$330.3K
NEIGHBORS BUILDING NEIGHBORHOODS OF MUSKOGEE INC
MUSKOGEE, OK
$328.5K
CHARLOTTESVILLE, VA
$325.8K
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
BOSTON, MA
$315K
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT BERKELEY
BERKELEY, CA
$310.1K
ALBANY, GA
$310K
GENEVA FOUNDATION
TACOMA, WA
$305.4K
UNIVERSITY OF SOUTHERN CALIFORNIA
LOS ANGELES, CA
$299.5K
UNIVERSITY OF OREGON
EUGENE, OR
$296.5K
MEMPHIS, TN
$283K
PISCATAWAY, NJ
$279.4K
UNIVERSITY OF CINCINNATI
CINCINNATI, OH
$271.4K
OREGON HEALTH & SCIENCE UNIVERSITY
PORTLAND, OR
$271K
GAINESVILLE, GA
$260K
KENNESAW, DC
$256.6K
THE UNIVERSITY OF MASSACHUSETTS
WORCESTER, MA
$255.6K
THE MIRIAM HOSPITAL
PROVIDENCE, RI
$254.6K
DANA-FARBER CANCER INSTITUTE
BOSTON, MA
$253.6K
LA JOLLA, CA
$253K
$251.1K
UNIVERSITY OF SOUTH FLORIDA
TAMPA, FL
$248.2K
CEDARS-SINAI MEDICAL CENTER
LOS ANGELES, CA
$244.3K
OLON USA LLC
CONCORD, OH
$242K
UTAH STATE UNIVERSITY
LOGAN, UT
$241.9K
SAVANNAH NEUROLOGY SPECIALISTS PC
SAVANNAH, GA
$237.3K
$234.9K
GRAND RAPIDS, MI
$230.6K
$224.9K
ROCHESTER, NY
$222.6K
UNIVERSITY OF TEXAS
AUSTIN, TX
$218.9K
ATLANTA, GA
$218.6K
NATIONAL ALLIANCE OF STATE AND TERRITORIAL AIDS DIRECTORS
WASHINGTON, DC
$215.8K
MD ANDERSON CANCER CENTER
HOUSTON, TX
$215.4K
THE PENNSYLVANIA STATE UNIVERSITY
UNIVERSITY PARK, PA
$215.3K
COLORADO STATE UNIVERSITY
FORT COLLINS, CO
$211.1K
THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM
MADISON, WI
$209.5K
KITWARE INC
CLIFTON PARK, NY
$209.1K
$208.1K
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
LA JOLLA, CA
$206.7K
CAMBRIDGE, MA
$204.3K
CHILDREN'S HOSPITAL CORPORATION
BOSTON, MA
$204.2K
APOPKA, FL
$202.4K
AUGUSTA, GA
$201.1K
$200K
WESTAT INC
ROCKVILLE, MD
$194.9K
UNIVERSITY OF NEW MEXICO
ALBUQUERQUE, NM
$186.4K
LSU HEALTH SCIENCES CTR-NEW ORLEANS
NEW ORLEANS, LA
$180.8K
TEXAS BIOMEDICAL RESEARCH INSTITUTE
SAN ANTONIO, TX
$178.3K
WASHINGTON, DC
$178.3K
MACON, GA
$173K
LSU HEALTH SCIENCES CTR-SHREVEPORT
SHREVEPORT, LA
$172.7K
UNIVERSITY OF IOWA
IOWA CITY, IA
$167.2K
WILLIAM MARCH RICE UNIVERSITY
HOUSTON, TX
$166.5K
DENVER HEALTH & HOSPITAL AUTHORITY
DENVER, CO
$161.9K
KLEIN BUENDEL INC
GOLDEN, CO
$155.8K
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
SEATTLE, WA
$150K
ATLANTA, GA
$150K
INOTIV INC
WEST LAFAYETTE, IN
$138.1K
INDIANA UNIVERSITY
BLOOMINGTON, IN
$137.8K
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
ALBUQUERQUE, NM
$137.2K
ATLANTA, GA
$135.8K
REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES
LOS ANGELES, CA
$135.5K
THE MASSACHUSETTS GENERAL HOSPITAL
SOMERVILLE, MA
$135.4K
$128K
RAPID CITY, SD
$127.7K
SIEMENS MEDICAL SOLUTIONS USA
PRINCETON, NJ
$126.1K
WASHINGTON, DC
$122.4K
ATLANTA, GA
$121.5K
PRINCETON, NJ
$115.3K
REGENTS OF THE UNIVERSITY OF CALIFORNIA
DAVIS, CA
$112.5K
UNIVERSITY OF SOUTH CAROLINA
COLUMBIA, SC
$112.1K
PROVIDENCE SACRED HEART MEDICAL CENTER
SPOKANE, WA
$111.9K
ARIZONA STATE UNIVERSITY
TEMPE, AZ
$110.4K
BETHEL, VT
$109K
SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION
SAN DIEGO, CA
$106.8K
NEW BRUNSWICK, NJ
$105K
$104.7K
UNIVERSITY OF GEORGIA
ATLANTA, GA
$104.6K
PHILADELPHIA, PA
$100.2K
VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO
SAN DIEGO, CA
$90.5K
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
BURLINGTON, VT
$89.4K
UNIVERSITY CORPORATION FOR ATMOSPHERIC
BOULDER, CO
$88K
LA JOLLA, CA
$87.6K
$87.4K
CHILDRENS HOSPITAL LOS ANGELES
LOS ANGELES, CA
$87.3K
WINSTONSALEM, NC
$86.4K
BIENESTAR HUMAN SERVICES INC
LOS ANGELES, CA
$86.4K
SAULT STE MARIE, MI
$86K
ST LOUIS, MO
$84.1K
UNIVERSITY OF KANSAS
KANSAS CITY, KS
$83.6K
MILWAUKEE, WI
$82.6K
NEW ORLEANS, LA
$81.4K
GEORGIA DEPARTMENT OF PUBLIC HEALTH
ATLANTA, GA
$76.9K
INDIANAPOLIS, IN
$75.8K
OHIO UNIVERSITY
ATHENS, OH
$75.2K
RHODE ISLAND HOSPITAL
PROVIDENCE, RI
$74.5K
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
LEXINGTON, KY
$73.9K
UNIVERSITY OF CONNECTICUT HEALTH CENTER
FARMINGTON, CT
$73.6K
RESUSCITATION ACADEMY FOUNDATION
SEATTLE, WA
$72.9K
ATLANTA, GA
$72.1K
PITTSBURGH, PA
$71.3K
UNIVERSITY OF MONTANA
MISSOULA, MT
$69.3K
OREGON STATE UNIVERSITY
CORVALLIS, OR
$69K
UNIVERSITY OF PUERTO RICO
SAN JUAN, PR
$69K
PRIMORDIA BIOSYSTEMS INC
COSTA MESA, CA
$68.7K
THE RAND CORPORATION
SANTA MONICA, CA
$67.2K
REGENTS OF THE UNIVERSITY OF COLORADO
DENVER, CO
$67.2K
ATLANTA, GA
$66.6K
THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
LITTLE ROCK, AR
$65.7K
LEBANON, NH
$62.5K
NEW YORK, NY
$61.5K
VETERANS HEALTH ADMINISTRATION
SEATTLE, WA
$59.9K
GEORGIA STATE UNIVERSITY
ATLANTA, GA
$59.8K
NORTH CAROLINA STATE UNIVERSITY
RALEIGH, NC
$59K
WESTERN WASHINGTON UNIVERSITY
BELLINGHAM, WA
$58.4K
UNIVERSITY OF ARKANSAS
FAYETTEVILLE, AR
$58K
PHILADELPHIA, PA
$56.8K
STETHX MICROSYSTEMS INC
ATLANTA, GA
$56.8K
VIRGINIA COMMONWEALTH UNIVERSITY
RICHMOND, VA
$55.8K
THE UNIVERSITY OF TEXAS AT SAN ANTONIO
SAN ANTONIO, TX
$55.2K
NORTH MIAMI, FL
$55K
HARVARD PILGRIM HEALTH CARE INC
CANTON, MA
$54.9K
Atlanta, GA
$54.3K
GEORGE MASON UNIVERSITY
FAIRFAX, VA
$54.1K
CALIFORNIA STATE UNIVERSITY LONG BEACH RESEARCH FOUNDATION
LONG BEACH, CA
$52.7K
CHEROKEE NATION
TAHLEQUAH, OK
$52.6K
$52K
SYNEOS HEALTH LLC
BOSTON, MA
$50.9K
CLEAR ANALYTICS
BOWIE, MD
$50.4K
INDEPENDENCE, OH
$49.8K
WINSTONSALEM, NC
$49.6K
TUFTS MEDICAL CENTER INC
BOSTON, MA
$49.3K
$48.3K
ECOGNOSIS LLC
WARWICK, RI
$46.2K
GEORGIA POLST COLLABORATIVE
STOCKBRIDGE, GA
$42.5K
THE MCLEAN HOSPITAL CORPORATION
SOMERVILLE, MA
$42.3K
STONY BROOK, NY
$42K
NEW YORK, NY
$40K
ATLANTA, GA
$40K
ALLEN INSTITUTE
SEATTLE, WA
$39K
BETHLEHEM, PA
$38.6K
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT SAN DIEGO
LA JOLLA, CA
$38.6K
PHILADELPHIA, PA
$38.4K
BOISE STATE UNIVERSITY
BOISE, ID
$38.4K
LOUISIANA STATE UNIVERSITY AND A&M COLLEGE
BATON ROUGE, LA
$37.8K
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIA
SAN ANTONIO, TX
$37.3K
UNIVERSITY OF NORTH CAROLINA GREENSBORO
GREENSBORO, NC
$37.1K
WASHINGTON, NY
$36.5K
ATLANTA, GA
$35.6K
ATLANTA, GA
$35.3K
$34.1K
TERRY, MS
$33.8K
WEST LAFAYETTE, IN
$33K
PUBLIC HEALTH INSTITUTE
OAKLAND, CA
$32.7K
ATLANTA, GA
$32.2K
VITALANT
SCOTTSDALE, AZ
$31.8K
$31.1K
BELMAR PHARMACY
GOLDEN, CO
$30.6K
STATE UNIVERSITY OF NEW YORK
ALBANY, NY
$30.6K
LAGRANGE, GA
$30K
ATLANTA, GA
$29.9K
NEW YORK, NY
$29.2K
ALBANY, GA
$29K
TEXAS TECH UNIVERSITY
LUBBOCK, TX
$28.9K
THE ACCESS TO ADVANCED HEALTH INSTITUTE
SEATTLE, WA
$28.2K
NATIONAL JEWISH HEALTH
DENVER, CO
$27K
WASHINGTON, DC
$26.2K
ATLANTA METROPOLITAN STATE COLLEGE
ATLANTA, GA
$25.6K
LA JOLLA, CA
$25.3K
Arlington, GA
$25K
WABE FOUNDATION INC
Atlanta, NY
$25K
INSCOPIX INC
MOUNTAIN VIEW, CA
$24.8K
COLUMBUS, GA
$24.7K
MENANDS, NY
$23.8K
TRUSTEES OF TUFTS COLLEGE
BOSTON, MA
$23.1K
ZABBIO INC
SAN DIEGO, CA
$22.5K
THE UNIVERSITY OF ARIZONA
TUCSON, AZ
$22.5K
PEROSPHERE TECHNOLOGIES INC
DANBURY, CT
$21.5K
EAST TENNESSEE STATE UNIVERSITY
JOHNSON CITY, TN
$21.1K
CLEMSON UNIVERSITY
CLEMSON, SC
$20.9K
SIOUX FALLS, SD
$20.3K
SWAINSBORO, GA
$20K
Smyrna, MA
$20K
HILL FIRST BAPTIST CHURCH
ATHENS, GA
$20K
ATLANTA, GA
$20K
Atlanta, GA
$20K
SAVANNAH, GA
$19.9K
EAST LANSING, MI
$19.2K
NORTHEASTERN UNIVERSITY
BOSTON, MA
$19K
TALLAHASSEE, FL
$18.9K
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
JACKSON, MS
$17.5K
BETH ISRAEL DEACONESS MEDICAL CENTER INC
BOSTON, MA
$17.2K
SILVER SPRING, MD
$17.2K
WASHINGTON, DC
$16.7K
$16.3K
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE
RIVERSIDE, CA
$16.3K
ATLANTA, GA
$16.2K
ATLANTA, GA
$16.2K
CHICAGO, IL
$15.8K
BALTIMORE, MD
$15.8K
HORIZONS COMMUNITY SOLUTIONS INC
ALBANY, GA
$15.3K
DOWNERS GROVE, IL
$15K
DAUGHTERS AGAINST ALZHEIMERS INC
Atlanta, GA
$15K
INFORMED HORIZONS EDUCATION INC
TUCKER, GA
$15K
NATIONAL ASSOCIATION OF HISPANIC NURSES INC
LEXINGTON, IL
$15K
RESTON, VA
$14.4K
COLQUITT COUNTY BOH - ELLENTON FARMWORKER CLINIC
ALBANY, GA
$14.4K
OKEMOS, MI
$13.8K
HAWTHORNE SPATIAL LLC
SAINT PAUL, MN
$13.7K
$13K
$12.5K
Roswell, GA
$12.5K
ATLANTA, GA
$12.4K
GULF BREEZE, FL
$12.1K
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
LUBBOCK, TX
$11.5K
AIDS FOUNDATION HOUSTON INC
HOUSTON, TX
$10K
NEW YORK, NY
$10K
DECATUR, GA
$10K
MEMPHIS, TN
$10K
GEORGIA DEPT OF NATURAL RESOURCES
Social Circle, GA
$10K
Griffin, GA
$10K
$10K
Boston, GA
$10K
$10K
ATLANTA, GA
$10K
NEW YORK, NY
$10K
NATIONAL BRAIN TUMOR SOCIETY INC
NEWTON, KY
$10K
DURHAM, NC
$10K
OPERATION HOPE INC
Atlanta, MA
$10K
BELLEROSE, NY
$10K
RENTON, WA
$10K
CHARLOTTE, NC
$10K
ATLANTA, GA
$10K
Port Washington, NY
$10K
WILTON MANORS, FL
$10K
TRANSFORMATIONS YOUTH GROUP
KANSAS CITY, MO
$10K
TRUE COLORS THEATRE COMPANY
ATLANTA, GA
$10K
WE LOVE BUFORD HIGHWAY INC
ATLANTA, GA
$10K
$9,859
THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
CHARLOTTE, NC
$9,600
KANSAS CITY, MO
$9,518
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE
IRVINE, CA
$8,475
ST LOUIS, MO
$8,369
THE UNIVERSITY OF MISSOURI
COLUMBIA, MO
$8,362
JACKSONVILLE, FL
$8,244
ALBANY, NY
$8,000
ATLANTA, GA
$8,000
NASHVILLE, TN
$8,000
GEORGIA PUBLIC LIBRARY SERVICE
ATLANTA, GA
$7,980
DETROIT, MI
$7,862
NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION INC
SAN FRANCISCO, CA
$7,778
MASS GENERAL BRIGHAM INCORPORATED
SOMERVILLE, MA
$7,338
MEMORIAL HEALTH MEADOWS PHYSICIANS
VIDALIA, GA
$6,666
THE UNIVERSITY OF TOLEDO
TOLEDO, OH
$6,303
Atlanta, GA
$6,000
GRAND BLANC, MI
$6,000
Chicago, GA
$6,000
$5,666
ARKANSAS BLACK GAY MENS FORM
LITTLE ROCK, AR
$5,500
GEORGIA BOARD OF NURSING
Macon, GA
$5,337
Showing the first 500 records.
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$19.8M
VA/DoD Award Count
2
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding (partial)
$2.5B
Awards Found
100+
Additional awards may exist. View all on USAspending.gov →
Department of Health and Human Services
$167M
SUPPORT OF YERKES NATIONAL PRIMATE RESEARCH CENTER
Department of Health and Human Services
$106M
NATIONAL EBOLA TRAINING AND EDUCATION CENTER
Department of Health and Human Services
$94.2M
ATLANTA CENTER FOR MICROSYSTEMS ENGINEERED POINT-OF-CARE TECHNOLOGIES (ACME POCT)
Department of Health and Human Services
$92.1M
GEORGIA CLINICAL & TRANSLATIONAL SCIENCE ALLIANCE (GACTSA)
Department of Health and Human Services
$73M
LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)
Department of Health and Human Services
$71.6M
B CELL AUTOIMMUNITY IN HUMAN SLE
Department of Health and Human Services
$67.8M
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
Department of Health and Human Services
$61.5M
OPEN DRUG DISCOVERY CENTER FOR ALZHEIMER'S DISEASE
Department of Health and Human Services
$59.7M
ANTIVIRAL COUNTERMEASURES DEVELOPMENT CENTER (AC/DC) - THE ANTIVIRAL COUNTERMEASURES DEVELOPMENT CENTER (AC/DC) WILL TARGET PATHOGENS IN FIVE FAMILIES OF RNA VIRUSES WITH SIGNIFICANT PANDEMIC POTENTIAL, WITH THE OVERARCHING GOAL TO IDENTIFY AND DEVELOP ORALLY BIOAVAILABLE, DIRECT ACTING ANTIVIRAL DRUGS (DAAS). SPECIFIC VIRAL TARGETS INCLUDE ZOONOTIC AND HUMAN VIRUSES IN THE CORONAVIRUS, PARAMYXOVIRUS, FLAVIVIRUS, PICORNAVIRUS, AND TOGAVIRUS FAMILIES. THE AC/DC MPIS DRS. PAINTER AND PLEMPER, WHO WILL LEAD THIS EFFORT, HAVE DEMONSTRATED THE POWER OF THEIR COMBINED EXPERTISE IN IDENTIFYING NOVEL ANTIVIRAL CHEMOTYPES AND ADVANCING THEM FROM HIT STAGE TO CLINICAL CANDIDATE, BEST EXEMPLIFIED BY THEIR SUCCESSFUL JOINT WORK ON MOLNUPIRAVIR, CONSIDERED FOR EMERGENCY APPROVAL AS THE FIRST ORAL THERAPEUTIC FOR THE TREATMENT OF COVID- 19. THE MPIS HAVE ASSEMBLED A TEAM OF RECOGNIZED EXPERTS IN THE BIOLOGY OF THE VIRAL PATHOGENS BEING TARGETED. THEIR EFFORTS ARE ORGANIZED INTO FIVE SYNERGISTIC PROJECTS SUPPORTED BY CUTTING-EDGE TECHNICAL EXPERTISE IN FIVE AC/DC SCIENTIFIC CORES, COVERING KEY AREAS OF PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT. A NUMBER OF THE CORE LEADERS HAVE SIGNIFICANT EXPERIENCE IN THE DEVELOPMENT OF ANTIVIRALS IN THE PHARMA AND BIOTECHNOLOGY SECTORS. THE AC/DC WILL ACHIEVE ITS OVERARCHING GOAL IN TWO MAJOR OBJECTIVES. PILOT STUDIES IDENTIFIED TWO CHEMICALLY DISTINCT BROAD-SPECTRUM RIBONUCLEOSIDE ANALOGS AND TWO NON-NUCLEOSIDE VIRAL POLYMERASE INHIBITORS WITH CONFIRMED ORAL EFFICACY AGAINST ONE OR SEVERAL OF THE FIVE VIRAL FAMILIES TARGETED, INCLUDING A NOVEL CHEMOTYPE THAT IS ORALLY EFFICACIOUS AGAINST SARS-COV-2 IN RELEVANT ANIMAL MODELS. OBJECTIVE 1 WILL ADVANCE THIS SET OF FOUR NOVEL DAA LEADS THROUGH FINAL SYNTHETIC OPTIMIZATION AND DE-RISKING IN ANIMAL MODELS AND PRIMARY HUMAN ORGANOIDS AS IMMEDIATE DELIVERABLES TO MITIGATE THE URGENT THREAT TO PUBLIC HEALTH. SIMULTANEOUSLY, OBJECTIVE 2 WILL IDENTIFY ADDITIONAL VIABLE HIT CHEMOTYPES TO EXPAND THE AC/DC'S ANTIVIRAL PORTFOLIO BY LEVERAGING CENTER EXPERTISE IN REVERSE GENETICS OF ALL VIRAL TARGET FAMILIES, EXISTING GROUNDBREAKING REPORTER VIRUS TECHNOLOGIES, AND HIGH-THROUGHPUT SCREENING UNDER STANDARD AND HIGH BIOCONTAINMENT CONDITIONS. HITS WILL BE COUNTERSCREENED AGAINST ALL CENTER TARGET FAMILIES, MOLECULAR VIRAL TARGETS AND MECHANISM OF ACTION CHARACTERIZED, AND A POTENCY, PHARMACOKINETICS, AND PHARMACOPHORE-DRIVEN SYNTHETIC DEVELOPMENT PROGRAM LAUNCHED TO IDENTIFY OPTIMIZED LEADS. ALL DATA GENERATED BY THE PROJECTS AND CORES WILL BE EVALUATED CENTER-WIDE UTILIZING QUANTITATIVE PERFORMANCE MILESTONES OF A DEFINED AC/DC LEAD ADVANCEMENT CASCADE THAT GOVERNS THE PROGRESSION OF A CHEMOTYPE FROM HIT TO CLINICAL DEVELOPMENT CANDIDATE.
Department of Health and Human Services
$59.4M
TOGETHER TAKEMEHOME: ACHIEVING SCALE AND IMPROVING ACCESS TO MAILED HIV SELF-TESTING FOR KEY US POPULATIONS - EMORY UNIVERSITY, COLLABORATION WITH BUILDING HEALTHY ONLINE COMMUNITIES, SIGNAL GROUP, ORASURE TECHNOLOGIES, AND NASTAD PROPOSE A PROGRAM THAT WILL USE AN ITERATIVE IMPROVEMENT PROCESS TO OPTIMIZE OUR EXISTING WEB-BASED ORDERING AND FULFILLMENT SYSTEMS AND INTEGRATE WITH CDC'S LET'S END HIV TOGETHER MARKETING CAMPAIGNS TO PROVIDE AT LEAST 875,000 AND UP TO 1 MILLION MAILED HIV SELF-TESTS OVER THE 5 YEAR PROGRAM WITH A FOCUS ON KEY US POPULATIONS, INCLUDING MSM, TRANSGENDER WOMEN, BLACK OR AFRICAN AMERICAN CISGENDER WOMEN, AND OTHER RESIDENTS OF PHASE 1 EHE AREAS. THE OVERARCHING PUBLIC HEALTH GOAL OF THE PROGRAM IS TO INCREASE AWARENESS OF HIV STATUS AND IMPROVE UTILIZATION OF OTHER HIV PREVENTION AND CARE SERVICES LEADING TO IMPROVED HEALTH AND REDUCTION IN HIV TRANSMISSION AMONG US POPULATIONS DISPROPORTIONATELY AFFECTED BY HIV. THE SPECIFIC SHORT TERM OUTCOMES FROM THE PROGRAM ARE: 1) CULTURALLY APPROPRIATE IMAGERY AND INFORMATION DEVELOPED BY CDC AVAILABLE ON THE SELF-TEST ORDERING PORTAL; 2) FULLY FUNCTIONAL COMPREHENSIVE HIVST DISTRIBUTION PROGRAM FOR PROCUREMENT, STORAGE, PROCESSING OF ORDERS AND PROGRAM MONITORING; 3) INCREASED ACCESS TO HIV SELF-TESTS AND PREVENTION SERVICES INCLUDING PREP AND STI TESTING AMONG PERSONS DISPROPORTIONATELY AFFECTED BY HIV; 4) INCREASED UNDERSTANDING OF STRATEGIES TO SUCCESSFULLY DELIVER HIV SELF-TESTS TO POPULATIONS DISPROPORTIONATELY AFFECTED BY HIV; AND 5) INCREASED UNDERSTANDING OF USER EXPERIENCE FOR HIV SELF-TESTING AMONG POPULATIONS DISPROPORTIONATELY AFFECTED BY HIV. THERE ARE ALSO INTERMEDIATE TERM OUTCOMES FROM THE PROGRAM: 1) INCREASED HIV TESTING AMONG POPULATIONS DISPROPORTIONATELY AFFECTED BY HIV AND 2) INCREASED NEW HIV DIAGNOSES AMONG POPULATIONS DISPROPORTIONATELY AFFECTED BY HIV. THE TOGETHER TAKEMEHOME (TTMH) PROGRAM IS THE NATIONAL SCALE-UP OF OUR EXISTING TAKEMEHOME PROGRAM THAT FOCUSES ON PROVIDING INFRASTRUCTURE FOR STATE/LOCAL HEALTH DEPARTMENTS TO ENGAGE IN MAILED HIVST DISTRIBUTION FOR THEIR RESIDENTS. THIS STATE/LOCAL PROGRAM WAS THE BASIS FOR THE NATIONWIDE TTMH DEMONSTRATION PROJECT, WHICH WILL BE REFINED AND RELAUNCHED FOR THE SCALE-UP PROGRAM. THE PROGRAM IMPLEMENTATION MODEL INVOLVES COLLABORATING WITH CDC TO IMPLEMENT REFINEMENTS TO OUR SYSTEMS AND MATERIALS AND IMPLEMENT MARKETING EFFORTS TO REFER KEY POPULATIONS TO THE TTMH WEB-PORTAL FOR ORDERING. THESE ORDERS ARE AUTOMATICALLY PROCESSED AND SENT TO AMAZON FULFILLMENT SERVICES. WE WILL CONSISTENTLY COMMUNICATE WITH PARTICIPANTS ON ORDER STATUS AND SEND REMINDERS FOR REPEAT ORDERING. IN ADDITION TO SELF-SERVICE WEB-PORTAL RESOURCES, TRAINED STAFF WILL BE AVAILABLE TO PROVIDE REFERRALS TO HIV/STI CARE AND PREVENTION SERVICES, INCLUDING PROVISION OF PREP NAVIGATION. THE PROGRAM WILL BE MONITORED AND EVALUATED WITH DATA FROM MULTIPLE SOURCES, INCLUDING ORDER INFORMATION, WEB-TRAFFIC/REFERRAL TRACKING, SURVEYS, AND QUALITATIVE INTERVIEWS. TO OPTIMIZE PROGRAM OUTCOMES, ITERATIVE IMPROVEMENTS WILL BE MADE TO THE TTMH SYSTEMS AND MATERIALS AND PROVIDE TIMELY INFORMATION TO CDC FOR REFINEMENT OF THEIR MARKETING EFFORTS.
Department of Health and Human Services
$59M
EMORY/ATLANTA CENTER FOR AIDS RESEARCH
Department of Health and Human Services
$46.7M
SUPPORT OF YERKES NATIONAL PRIMATE RESEARCH CENTER
Department of Health and Human Services
$46M
EMORY HIV/AIDS CLINICAL TRIALS UNIT
Department of Health and Human Services
$44.7M
SYSTEMS BIOLOGICAL ANALYSIS OF INNATE AND ADAPTIVE RESPONSES TO VACCINATION
Department of Health and Human Services
$44.3M
EMORY WINSHIP CANCER INSTITUTE CANCER CENTER SUPPORT GRANT
Department of Health and Human Services
$42.3M
B AND T CELL BIOLOGY OF PROTECTION FROM AND ERADICATION OF SIV/SHIV INFECTION
Department of Health and Human Services
$40M
THE DIABETES MATCH INITIATIVE: MOBILIZING ACCESS THROUGH CAPACITY BUILDING AND HEALTH EQUITY - <![CDATA[THE PURPOSE OF THIS FUNDED PROJECT, A STRATEGIC APPROACH TO ADVANCING HEALTH EQUITY FOR PRIORITY POPULATIONS WITH OR AT RISK FOR DIABETES—SUBJECT MATTER EXPERTISE, TRAINING, AND TECHNICAL ASSISTANCE (CDC-RFA-DP-23-0021) IS TO SUPPORT THE GOALS OF THE COMPANION FUNDING OPPORTUNITY, A STRATEGIC APPROACH TO ADVANCING HEALTH EQUITY FOR PRIORITY POPULATIONS WITH OR AT RISK FOR DIABETES (CDC-RFA-DP23-0020). OVER THE NEXT FIVE YEARS, THE SUBJECT MATTER EXPERTISE, TRAINING, AND TECHNICAL ASSISTANCE PROVIDED BY THE EMORY CENTERS FOR PUBLIC HEALTH TRAINING AND TECHNICAL ASSISTANCE (EMORY CENTERS) AND ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS (ADCES) TEAM WILL STRENGTHEN AND BUILD NEW CAPACITIES OF THE DP-23-0020 RECIPIENTS TO SUCCESSFULLY ACHIEVE THE SPECIFIC OUTCOMES OF THEIR PROJECTS AND SHARED MEASURES OF COLLECTIVE IMPACT ACROSS PROJECTS TO DECREASE THE RISK FOR TYPE 2 DIABETES AMONG ADULTS WITH PREDIABETES AND IMPROVE SELF-CARE PRACTICES, QUALITY OF CARE, AND EARLY DETECTION OF COMPLICATIONS AMONG PRIORITY POPULATIONS WITH DIABETES. OUR SPECIFIC AIM IS TO INCREASE CAPACITY AMONG DP23-0020 RECIPIENTS TO IMPROVE HEALTH EQUITY, WITH THREE 5-YEAR IMPACT GOALS: 1) INCREASING ACCESS TO AND DELIVERY OF DIABETES MANAGEMENT; 2) INCREASING ACCESS TO AND DELIVERY OF TYPE 2 DIABETES PREVENTION; AND 3) INCREASING ACCESS TO AND DELIVERY OF RISK REDUCTION INTERVENTIONS FOR PRIORITY POPULATIONS. TOGETHER, EMORY CENTERS AND ADCES BRING AN INCREDIBLY RICH DIVERSITY OF NATIONWIDE SYSTEMS, COMMUNITY PARTNERS, AND SMES THAT WILL BE JOINING OUR NETWORK. OUR ORGANIZATIONS ARE HIGHLY RESPECTED, RECOGNIZED, AND TRUSTED BY OUR FUNDERS, PEERS, AND COMMUNITIES WE SERVE. COLLECTIVELY, WE ARE COMMITTED TO ENSURING THE QUALITY OF NATIONWIDE DIABETES PROGRAMS AND THEIR DELIVERY IN ALL PRIORITY POPULATIONS AND PROVIDING THE CAPACITY BUILDING FOR RECIPIENTS TO INCREASE ACCESS, UPTAKE, AND IMPACTFUL IMPLEMENTATION THROUGH LOCAL ADAPTATION AND FLEXIBILITY. OUR ORGANIZATIONAL MODEL TO ACCOMPLISH THE AIMS OF THIS WORK IS TO CREATE THE DIABETES MATCH INITIATIVE WHICH STANDS FOR MOBILIZING ACCESS THROUGH CAPACITY BUILDING AND HEALTH EQUITY. IT EMPHASIZES OUR EXPERIENCE WITH A COLLECTIVE IMPACT APPROACH THAT INTEGRATES THE STRENGTH OF EMORY-ADCES WORKING TOGETHER WITH OTHER SME COMMUNITY PARTNERS AND SYSTEMS IN ALL ASPECTS OF THE WORK. THIS WILL BE LED BY EMORY CENTERS’ EXECUTIVE DIRECTOR, DR. LINELLE BLAIS, WHO WILL SERVE AS THE EXECUTIVE DIRECTOR FOR THE MATCH INITIATIVE AND OVERSEE THE MANAGEMENT OF THE PROJECT AND ADVISE ON OVERARCHING STRATEGIC APPROACHES. DR. LILLIAN MADRIGAL, DIRECTOR OF IMPLEMENTATION SCIENCE AND PRACTICE AT EMORY CENTERS, WILL SERVE AS THE EMORY DIRECTOR ALONG WITH PAULINA DUKER, MPH, RN, CDCES, ADCES’ VICE PRESIDENT OF PRACTICE & LEARNING AS THE ADCES DIRECTOR. THERE WILL BE SIX CORE TEAMS WITH LEADS REPRESENTING BOTH EMORY AND ADCES; THREE TEAMS ARE ALIGNED TO THE THREE STRATEGY AREAS (SME NETWORK, TRAINING & TA, GUIDANCE DOCUMENTS & RESOURCES), AND THREE TEAMS ARE ALIGNED TO CROSS STRATEGY CORES (HEALTH EQUITY FOR PRIORITY POPULATIONS, PROGRAM EVALUATION & HEALTH EQUITY STUDIES, AND COMMUNICATIONS & DESIGN). CORES WILL BE LED BY EXPERTS IN DIABETES, HEALTH EQUITY, TRAINING, AND TA (DESCRIBED IN THE POSITION DESCRIPTIONS). LASTLY, THE MATCH INITIATIVE WILL ALSO INCLUDE THE MATCH INITIATIVE ADVISORY GROUP MADE UP OF SELECT REPRESENTATIVES FROM THE DP23-0020 RECIPIENTS AND PARTNERS FROM OUR SME NETWORK.]]>
Department of Health and Human Services
$39.9M
TRANSPLANT TOLERANCE IN NON-HUMAN PRIMATES
Department of Health and Human Services
$39.8M
VACCINE AND TREATMENT EVALUATION UNITS
Department of Health and Human Services
$35.2M
THE EMORY HEALTHY BRAIN STUDY: DISCOVERING PREDICTIVE BIOMARKERS FOR ALZHEIMER'S DISEASE - ABSTRACT/SUMMARY PROGRESS IN UNDERSTANDING ALZHEIMER’S DISEASE AND RELATED DISORDERS (ADRD) IS CLOSE TO PRODUCING MORE EFFECTIVE TREATMENTS, CREATING AN URGENT NEED FOR DISEASE-PREDICTIVE BIOMARKERS TO GUIDE THEIR USE. USING CEREBROSPINAL FLUID (CSF) MEASUREMENTS OF BETA-AMYLOID AND TAU AND POSITRON-EMISSION TOMOGRAPHY TRACERS, WE CAN DETECT AD PATHOLOGY IN COGNITIVELY NORMAL INDIVIDUALS. HOWEVER, CURRENT TOOLS DO NOT ALLOW US TO PREDICT WHEN OR EVEN IF AN INDIVIDUAL WITH ASYMPTOMATIC PATHOLOGY WILL DEVELOP SYMPTOMS. TO ADDRESS THIS NEED, WE PROPOSE TO LONGITUDINALLY STUDY =3000 COGNITIVELY NORMAL INDIVIDUALS (50-75 YEARS AT ENROLLMENT) IN THE EMORY HEALTHY BRAIN STUDY TO DEFINE THE FREQUENCY OF ASYMPTOMATIC AD AND RATES OF COGNITIVE DECLINE IN A RACIALLY DIVERSE COHORT OF HEALTHY INDIVIDUALS (SPECIFIC AIM 1). AN IMPORTANT GOAL OF AIM 1 IS TO ACHIEVE =33% AFRICAN- AMERICAN PARTICIPANTS TO PROVIDE SUFFICIENT POWER TO ADDRESS QUESTIONS REGARDING RACE- AND SEX-DEPENDENT DIFFERENCES IN BIOMARKERS AND RISK OF COGNITIVE DECLINE. PARTICIPANTS WILL BE PHENOTYPED BIENNIALLY WITH COGNITIVE TESTING, CARDIOVASCULAR PHYSIOLOGY, BRAIN MRI, AND BLOOD AND CSF COLLECTION. CROSS-SECTIONAL (SPECIFIC AIM 2) AND LONGITUDINAL ANALYSES (SPECIFIC AIM 3) WILL TEST THE HYPOTHESIS THAT BIOMARKERS OF SYNAPTIC, VASCULAR, MYELINATION, GLIAL IMMUNITY, AND METABOLIC FUNCTIONS WILL IDENTIFY SUBGROUPS WHO ARE AT GREATEST RISK OF PROGRESSING TO SYMPTOMATIC AD. CANDIDATE BIOMARKERS WILL BE IDENTIFIED THROUGH STATE-OF-THE-ART PROTEOMICS, MR IMAGING, AND STATISTICAL METHODS. A HIGHLY COLLABORATIVE DATA AND BIOSPECIMEN SHARING PLAN WILL ALLOW OTHER INVESTIGATORS TO LEVERAGE THESE RESOURCES TO ADVANCE A BROAD SPECTRUM OF ADRD RESEARCH.
Department of Health and Human Services
$32M
B AND T CELL BIOLOGY OF PROTECTION FROM AND ERADICATION OF SIV/SHIV INFECTION - ABSTRACT THE EMORY CONSORTIUM FOR INNOVATIVE HIV/AIDS VACCINE AND CURE RESEARCH IN NONHUMAN PRIMATES AIMS TO DEFINE THE MECHANISMS OF THE B AND T CELL BIOLOGY OF PROTECTION FROM AND ERADICATION OF SHIV INFECTION. THE CONSORTIUM BRINGS TOGETHER AN INTERDISCIPLINARY MIX OF HIGHLY COLLABORATIVE, AND PRODUCTIVE INVESTIGATORS IN A RANGE OF HIV VACCINE AND CURE DISCIPLINES TO ADDRESS THE OVERARCHING HYPOTHESIS THAT THE SUCCESS OF THE PROPHYLACTIC HIV VACCINE WE HAVE DEVELOPED DURING THE CURRENT PROGRAM IS DUE TO A COMBINATION OF A STRONG AND SUSTAINED SYSTEMIC AND MUCOSAL IMMUNE RESPONSE. THIS IS COMPRISED OF MULTI-FUNCTIONAL ANTIBODY AND TISSUE RESIDENT CD8 T CELL IMMUNITY, WHICH UPON ENCOUNTERING COGNATE ANTIGEN RESPONDS THROUGH CONVENTIONAL CYTOLYTIC MECHANISMS AND THROUGH MODULATION OF THE MUCOSAL ENVIRONMENT, SUCH THAT RESPONDING HIV-SPECIFIC CD4+ T CELL ARE RESISTANT TO INFECTION. MOREOVER, WE POSTULATE THAT SUCH A POTENT AND BALANCED VACCINE RESPONSE WILL, IN THE CONTEXT OF ACTIVE LATENCY REVERSING AGENTS, REDUCE VIRAL RESERVOIRS AND THUS MAINTAIN SUPPRESSION OF VIRUS REPLICATION FOLLOWING CESSATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. THE APPROACHES IN FOCUS 1, AIMED AT UNDERSTANDING THE MECHANISMS OF VACCINE PROTECTION, WILL UTILIZE STATE OF THE ART TECHNIQUES AND ANALYSES TO FULLY CHARACTERIZE AND HARNESS A NOVEL POPULATION OF TISSUE RESIDENT CD8 T CELLS INDUCED BY OUR HETEROLOGOUS VIRAL VECTOR VACCINE (HVV VACCINE) ENCODING GAG AS AN IMMUNOGEN TO EFFECTIVELY SYNERGIZE WITH THE HUMORAL IMMUNE RESPONSE INDUCED BY OUR HIV ENVELOPE TRIMER VACCINE (PROTEIN VACCINE) CO-DELIVERED WITH NOVEL ADJUVANTS TO PROVIDE LONG-TERM PROTECTION AGAINST HETEROLOGOUS SHIV CHALLENGE EVEN IN THE ABSENCE OF STRONG NEUTRALIZING ANTIBODY RESPONSE. IN THE LATER YEARS WE WILL USE THIS NOVEL, MECHANISTIC INFORMATION TO OPTIMIZE THE VACCINE AND MOVE IT CLOSER TO CLINICAL STUDIES. IN FOCUS 2 WE WILL PURSUE, IN SHIV-INFECTED ART-TREATED MACAQUES, THE “SHOCK AND KILL” APPROACH TO INDUCE VIRUS EXPRESSION FROM LATENTLY INFECTED CELLS USING LATENCY REVERSAL AGENTS (LRAS) FOLLOWING THERAPEUTIC VACCINATION AIMED AT BOOSTING VIRUS- SPECIFIC IMMUNE RESPONSES ABLE TO CLEAR CD4 T CELLS IN WHICH VIRUS PRODUCTION HAS BEEN REACTIVATED. FIRST, WILL DETERMINE HOW THE HVV+PROTEIN VACCINE BEHAVES IN ART SUPPRESSED MACAQUES AND THEN STUDY ITS ABILITY TO DEPLETE THE RESERVOIR IN THE CONTEXT OF ACTIVE LRAS AND ITS IMPACT ON CONTROL OF VIRAL REBOUND. THESE EXPERIMENTAL APPROACHES WILL BE SUPPORTED BY AN EFFECTIVE OPERATIONS AND MANAGEMENT SUPPORT COMPONENT AND THREE STATE OF THE ART CENTRALIZED RESEARCH RESOURCES TO FULLY CHARACTERIZE THE MAGNITUDE, FUNCTION, SPECIFICITY AND REPERTOIRE OF THE HUMORAL RESPONSE. SINGLE CELL ANALYSIS AND TRANSCRIPTOMICS WILL ALSO SUPPORT CHARACTERIZATION OF INNATE AND ADAPTIVE SIGNALS AT THE CELLULAR LEVEL.
Department of Health and Human Services
$31.1M
HOUSEHOLD AIR POLLUTION AND HEALTH: A MULTI-COUNTRY LPG INTERVENTION TRIAL
Department of Health and Human Services
$30M
ENTERPRISE FOR RESEARCH AND ADVOCACY TO STOP AND ERADICATE HIV (ERASE-HIV) - ABSTRACT THE PRESENCE OF A RESERVOIR OF CELLS HARBOURING INTEGRATED, REPLICATION-COMPETENT VIRUS THAT PERSISTS UNDER LONG- TERM, FULLY SUPPRESSIVE ANTIRETROVIRAL THERAPY (ART) AND THE INABILITY OF THE HOST IMMUNE RESPONSES TO CONTROL THE INITIAL EVENTS OF VIRAL REPLICATION THAT FOLLOW ART INTERRUPTION ARE CRITICAL BARRIERS TO CURING HIV INFECTION. THUS, NOVEL THERAPEUTIC STRATEGIES TO REMOVE THESE BARRIERS ARE CRITICALLY NEEDED. THE OVERARCHING HYPOTHESES OF ERASE HIV ARE: (I) DECREASED AND/OR DYSFUNCTIONAL CD8+ T AND NK CELL ANTIVIRAL FUNCTIONS, COMBINED WITH THE RECENTLY-DESCRIBED CD8+ T-CELL-MEDIATED TRANSCRIPTIONAL SILENCING OF HIV, FAVOUR HIV PERSISTENCE UNDER ART AND PREVENT THE CONTROL OF VIREMIA IF ART IS STOPPED; AND (II) NOVEL APPROACHES TO ELICIT EFFECTIVE CD8+ T-CELL, NK CELL, AND ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) FUNCTIONS WHILE INHIBITING THE CD8+ T-CELL-MEDIATED VIRUS SILENCING WILL PROMOTE REMISSION AND/OR ERADICATION OF HIV. THE OVERARCHING GOAL OF ERASE HIV IS TO IDENTIFY NOVEL MECHANISMS OF HIV PERSISTENCE AND TO TEST THEM IN THE MOST RELEVANT PRE-CLINICAL ANIMAL MODELS THROUGH MECHANISTICALLY-ORIENTED, COMMUNITY-SUPPORTED THERAPEUTIC STRATEGIES THAT CAN BE ULTIMATELY TRANSLATED TO CURE HIV INFECTION IN HUMANS. ERASE HIV INCLUDES THREE HIGHLY INTEGRATED RESEARCH FOCI (RFS). RF1 IS AIMED AT IDENTIFYING THE MOLECULAR AND CELLULAR MECHANISMS UNDERLYING THE TWO DISTINCT ANTIVIRAL ACTIVITIES OF CD8+ T-CELLS: THE MHC-RESTRICTED, AG-SPECIFIC RESPONSE THAT DIRECTLY ELIMINATES VIRUS-INFECTED CELLS, AND THE NON-MHC RESTRICTED, NON-CYTOLYTIC SILENCING OF HIV TRANSCRIPTION. AS SUCH, RF1 WILL PROVIDE THE CONCEPTUAL BASIS FOR THE INTERVENTIONS TESTED IN RF2 AND RF3. RF2 WILL USE ANIMAL MODELS OF ART-TREATED HIV INFECTION TO (I) RESTORE CD8+ T AND NK CELL FUNCTION WITH A COMBINED A-IL-10 AND IL-15 SUPERAGONIST (N-803) STRATEGY; (II) TARGET REBOUNDING VIRUS BY USING A CD4-MIMETIC COMPOUND (CD4MC) TO ENHANCE ANTIBODY RECOGNITION OF CELLS EXPRESSING HIV ENV AND THEIR ELIMINATION VIA ADCC; AND (III) DETERMINE IF IMPROVING CD8 T AND NK CELL FUNCTION VIA A-IL-10 AND N- 803 SYNERGIZES WITH CD4MC TO CLEAR INFECTED CELLS. RF3 WILL DETERMINE IF SUPPRESSION OF THE LATENCY-PROMOTING ACTIVITY OF CD8+ T-CELLS, COUPLED WITH N-803 AND INTERVENTIONS TO PROMOTE APOPTOSIS (BCL-2 INHIBITORS) OR IMMUNE- MEDIATED REMOVAL (CD4MC) OF CELLS THAT HAVE REACTIVATED VIRUS, WILL REDUCE THE RESERVOIR SIZE. IN ALL, WE WILL EXPLOIT THE SYNERGY BETWEEN THE MECHANISTIC DATA GENERATED IN RF1 AND THE IN VIVO INTERVENTIONS IN RF2 AND RF3 TO VALIDATE A STRATEGY THAT TARGETS BOTH HIV PERSISTENCE DURING ART AND HIV RECRUDESCENCE AFTER ART INTERRUPTION. ERASE HIV IS SUPPORTED BY EXPERTS IN HIV ADVOCACY (SISTERLOVE); RECOGNITION AND KILLING OF HIV ENV-EXPRESSING CELLS (FINZI/SODROSKI); T AND NK CELL BIOLOGY (SEKALY/RIBEIRO/DELEAGE/PARSONS); RESERVOIR ASSAYS AND LATENCY MODELS (KULPA/JONES/LITCHTERFELD/HOWELL); PRE-CLINICAL ANIMAL STUDIES (PAIARDINI/SILVESTRI/GARCIA/SAEZ- CIRION/KEELE/KUMAR); MATHEMATICAL MODELLING (DAVENPORT); AND THERAPEUTICS DEVELOPMENT (MERCK AND IMMUNITYBIO) FOR HIV CURE. WE BELIEVE THAT THE PROPOSED MECHANISTICALLY-ORIENTED PRE-CLINICAL WORK WILL INFORM STRATEGIES THAT CAN BE TRANSLATED IN CLINICAL TRIALS TO ACHIEVE PROLONGED VIRAL REMISSION IN PWH.
Department of Health and Human Services
$26.7M
CUREIT: CURING THE UNCURABLE VIA RNA-ENCODED IMMUNOGENE TUNING - MORE THAN 25 MILLION AMERICANS CURRENTLY LIVE WITH AUTOIMMUNE DISEASE, AND ALMOST TWO MILLION ARE PROJECTED TO BE DIAGNOSED WITH CANCER IN 2023. IMMUNE DYSREGULATION IS AN UNDERLYING COMPONENT OF NOT ONLY CANCER AND AUTOIMMUNE DISEASES, BUT ALSO INFECTIOUS DISEASES, TRANSPLANT REJECTION, AND OTHER COMMON MEDICAL CONDITIONS. CURRENT METHODS OF IMMUNE MODULATION USED TO TREAT AND MITIGATE THESE CONDITIONS ARE OFTEN EXPENSIVE OR NOT COMPLETELY EFFECTIVE. CURING THE UNCURABLE VIA RNA-ENCODED IMMUNOGENE TUNING (CUREIT) AIMS TO ADDRESS IMMUNE DYSREGULATION BY DIRECTLY PROGRAMMING IMMUNE CELL FUNCTION. ADVANCES IN GENE-ENCODED TECHNOLOGY WILL BE LEVERAGED TO DEVELOP A PLATFORM CAPABILITY ABLE TO BOTH ENHANCE PROTECTIVE IMMUNE RESPONSES AS WELL AS MODULATE INSUFFICIENT OR INEFFECTIVE IMMUNE PROFILES. CUREIT SEEKS TO DEVELOP A DISEASE-AGNOSTIC TOOLBOX OF METHODS AND TECHNOLOGIES, INCLUDING THE IN VIVO DELIVERY OF MRNA-BASED DRUGS, CELL TARGETING LIPID NANOPARTICLES, AND EX VIVO MODULATION OF IMMUNE CELLS. THIS TECHNOLOGY HAS THE POTENTIAL TO MAKE SIGNIFICANT ADVANCEMENTS TOWARDS MANAGING OR ELIMINATING MANY DISEASES AND CONDITIONS AFFECTING ALL AGES AND DEMOGRAPHICS, INCLUDING DISEASES WHICH ARE CURRENTLY UNTREATABLE.
Department of Health and Human Services
$25.7M
ATLANTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (ACTSI) RENEWAL
Department of Health and Human Services
$25.5M
PLASMA CELLS IN HEALTH AND DISEASE
Department of Health and Human Services
$24.6M
INSTITUTIONAL RESEARCH AND ACADEMIC CAREER DEVELOPMENT
Department of Health and Human Services
$24.5M
EMORY ALZHEIMER'S DISEASE RESEARCH CENTER
Department of Health and Human Services
$24.2M
ATLANTA MACS/WIHS COMBINED COHORT STUDY CLINICAL RESEARCH SITE
Department of Health and Human Services
$23.5M
ATLANTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1)
Department of Health and Human Services
$21.8M
SILVIO O. CONTE CENTER FOR OXYTOCIN AND SOCIAL COGNITION
Department of Education
$21.4M
EMERGENCY FINANCIAL AID GRANTS TO INSTITUTIONS UNDER THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT
Department of Health and Human Services
$21.2M
THE EMORY ALZHEIMER'S DISEASE CENTER
Department of Health and Human Services
$21.1M
B-CELL BIOLOGY OF MUCOSAL IMMUNE PROTECTION FROM SIV CHALLENGE
Department of Health and Human Services
$20.9M
HERCULES: HEALTH AND EXPOSOME RESEARCH CENTER AT EMORY
National Science Foundation
$20.6M
CCI CENTER IN SELECTIVE C-H FUNCTIONALIZATION
Department of Health and Human Services
$20.5M
DIVERSE ROLES OF REACTIVE OXYGEN SPECIES AND INFLAMMATION IN VASCULAR DISEASE
Department of Health and Human Services
$20.1M
MECHANISMS OF RISK AND RESILIENCE IN ASD: ONTOGENY, PHYLOGENY AND GENE DISRUPTION
Department of Health and Human Services
$20M
ROLE OF ANTIGEN-SPECIFIC T CELL RESPONSES IN THE CONTROL OF TB
National Science Foundation
$20M
NSF CENTER FOR SELECTIVE CH FUNCTIONALIZATION
Department of Health and Human Services
$19.7M
CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) EXPANSION AND MODERNIZATION
Department of Education
$18.1M
EMERGENCY FINANCIAL AID GRANTS TO STUDENTS UNDER THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT
Department of Health and Human Services
$18M
CTL AND HIV POLYMORPHISMS IN HETEROSEXUAL TRANSMISSION
Department of Health and Human Services
$17.9M
SERIOUS HAZARDS OF TRANSFUSION & CELLULAR THERAPIES: MECHANISMS AND INTERVENTION
Department of Health and Human Services
$16.1M
AIDS EDUCATION TRAINING CENTERS
Department of Health and Human Services
$16M
MAINTENANCE OF THE SPF BREEDING COLONIES AT YERKES NATIONAL PRIMATE RESEARCH CENTER
Department of Health and Human Services
$15.2M
EMORY WIHS CRS - LONGITUDINAL COHORT
Department of Health and Human Services
$14.9M
CONSTRUCTION OF A DUAL FUNCTION PRIMATE FACILITY: ABSL3 AND TRANSPLANT MEDICINE
Department of Health and Human Services
$14.1M
INSTITUTIONAL CAREER DEVELOPMENT
Department of Health and Human Services
$14M
HARVARD/MICHIGAN PROSTATE CANCER BIOMARKER CLINICAL CTR
Department of Health and Human Services
$13.5M
EMORY PREVENTION RESEARCH CENTER
Department of Health and Human Services
$13.4M
GEORGIA DIABETES TRANSLATION RESEARCH CENTER
Department of Health and Human Services
$13.3M
CORRELATES OF PROTECTIVE IMMUNITY TO HCV AND RATIONAL VACCINE DESIGN - ABSTRACT PREVENTION OF HCV INFECTION REMAINS AN IMPORTANT PUBLIC HEALTH OBJECTIVE EVEN WITH THE RECENT ADOPTION OF HIGHLY EFFECTIVE ANTIVIRAL THERAPIES. IMPORTANTLY, TREATMENT WITH DIRECT ACTING ANTIVIRALS (DAAS) DOES NOT PREVENT REINFECTION IN THOSE WHO HAVE SUCCESSFULLY BEEN TREATED. A VACCINE TO PREVENT HCV PERSISTENCE IS NEEDED TO STEM AN EMERGING EPIDEMIC OF INFECTION IN ADOLESCENTS AND YOUNG ADULTS WHO INJECT DRUGS THAT HAVE LIMITED ACCESS TO SCREENING AND TREATMENT. ONLY TWENTY FIVE PERCENT OF ACUTE HCV INFECTIONS RESOLVE SPONTANEOUSLY. RESOLUTION DOES, HOWEVER, SHARPLY REDUCE THE RISK OF PERSISTENT INFECTION UPON RE-EXPOSURE TO THE VIRUS. MEMORY CD4+ T HELPER AND CD8+ CYTOTOXIC T CELL RESPONSES CONTRIBUTE TO ACCELERATED CLEARANCE OF A SECOND INFECTION. HOWEVER, THE ROLE OF NEUTRALIZING ANTIBODIES DURING REINFECTION IS LESS CLEAR. IMPORTANTLY, VACCINES TO GENERATE AN EQUIVALENT T CELL RESPONSE FAILED TO THWART OFF THE RATE OF PERSISTENCE IN NAÏVE RECIPIENTS. HERE, WE WILL TEST THE CENTRAL HYPOTHESIS THAT MEMORY CD4+ T CELLS CONTRIBUTE SIGNIFICANTLY TO HCV REINFECTION OUTCOME BY PROMOTING EXPANSION OF HCV-SPECIFIC B CELLS AND PRODUCTION OF BROADLY NEUTRALIZING ANTIBODIES THAT CONTRIBUTE TO VIRAL CLEARANCE. UNIQUE FEATURES OF THIS PROPOSAL ARE (I) THE USE OF LONGITUDINAL SAMPLES FROM THE MONTREAL COHORT OF HIGH- RISK PEOPLE WHO INJECT DRUGS. PARTICIPANTS ARE MONITORED PRIOR TO, DURING, AND AFTER HCV INFECTION AND THEN SUBSEQUENTLY FOLLOWED AGAIN WHEN THEY HAVE BEEN RE-EXPOSED TO HCV A SECOND TIME AFTER RESOLVING THEIR PRIMARY INFECTION. (II) WE HAVE ASSEMBLED A TEAM OF INVESTIGATORS IN CAIRO, EGYPT WHO WILL ASSIST US WITH RECRUITING AND TREATING SUBJECTS UNDERGOING DAA TREATMENT. EGYPT HAS THE HIGHEST PREVALENCE OF HCV INFECTION IN THE WORLD. IN 2014, EGYPT'S GOVERNMENT HAS MADE DAA TREATMENT AFFORDABLE AND 2.5 MILLION SUBJECTS HAVE STARTED TREATMENT. UNDERSTANDING THE IMMUNE RESPONSES IN THESE TWO COHORTS WILL PROVIDE US WITH VALUABLE INFORMATION TO DEVELOP AN EFFICACIOUS VACCINE REGIMEN THAT WOULD EMULATE THE SUCCESSFUL RESPONSES GENERATED DURING A NATURAL CHALLENGE WITH HCV. THREE HIGHLY INTERACTIVE PROJECTS ARE PROPOSED. PROJECT 1 (N. SHOUKRY, PI) WILL COMPARE THE FREQUENCY, BREADTH, FUNCTION, AND PHENOTYPE OF CD4+ T CELLS IN HCV REINFECTIONS THAT EITHER RESOLVE OR BECOME PERSISTENT. PROJECT 2 (A. GRAKOUI, PI) WILL USE NEW STATE OF THE ART TECHNOLOGY TO ISOLATE AND CHARACTERIZE ANTIGEN-SPECIFIC B CELLS DURING HCV REINFECTION AND POST DAA TREATMENT. PROJECT 3 (R. AMARA, PI) WILL DEVELOP VACCINE MODALITIES TO INDUCE BOTH A CD4+ T HELPER RESPONSE AND A ROBUST ANTIGEN-SPECIFIC ANTIBODY RESPONSE IN BLOOD AND LIVER USING DNA, MODIFIED VACCINIA ANKARA (MVA) AND PROTEIN-BASED VACCINES AGAINST HCV PROTEINS IN NON-HUMAN PRIMATES.
Department of Health and Human Services
$13M
MEDICAL SCIENTIST TRAINING PROGRAM
Department of Health and Human Services
$12.9M
NATIONAL EBOLA TRAINING AND EDUCATION CENTER (NETEC) SUPPLEMENT
Department of Health and Human Services
$12.8M
P-CARRS-BRAIN: MULTI-DOMAIN (GENETIC, SOCIO-BEHAVIORAL, VASCULAR) RISK FACTORS AND PREDICTION OF ALZHEIMER’S DISEASE CONTINUUM IN SOUTH ASIANS IN INDIA - PROJECT SUMMARY/ABSTRACT WHILE IT IS WIDELY ACKNOWLEDGED THAT ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (AD/ADRD) HAVE AN EXTENDED PRECLINICAL PHASE, THERE ARE SPARSE DATA ON THE COGNITIVE AND PATHOBIOLOGICAL CHANGES IN MIDDLE-AGES, A CRITICAL WINDOW FOR PREVENTATIVE INTERVENTION IN PEOPLE LIKELY TO PROGRESS TO FULL-BLOWN CLINICAL DISEASE. SOUTH ASIANS, A POPULATION WITH HEIGHTENED RISK OF AD/ADRD AND VASCULAR/METABOLIC RISKS AT YOUNGER AGES, OFFER A UNIQUE OPPORTUNITY TO INVESTIGATE PRECLINICAL AD/ADRD AND RELATED MODIFIABLE RISK FACTORS OF ITS PROGRESSION. PREDICTIVE MODELS LEVERAGING MULTIMODAL DATA COULD TRANSFORM PROSPECTS FOR EARLY AD/ADRD DETECTION AND PHENOTYPE IDENTIFICATION IN MIDDLE-AGED PEOPLE, BUT ARE CURRENTLY LACKING. TO ADDRESS THESE GAPS, WE PROPOSE TO EFFICIENTLY LEVERAGE THE NHLBI-FUNDED PPG, THE PRECISION-CARRS COHORT (P01HL154996; N=21,864), WHICH HAS ~15 YEARS OF DETAILED, REPEATED MEASURES OF SOCIO-BEHAVIORAL, ENVIRONMENTAL, AND VASCULAR/METABOLIC DATA. OUR SPECIFIC AIMS ARE: (AIM-1) PERFORM MULTIMODAL AD/ADRD PHENOTYPING AND GENETICALLY CHARACTERIZE THE RISK OF AD/ADRD ACROSS THE CONTINUUM; (AIM-2) INVESTIGATE MODIFIABLE RISK FACTORS (SOCIO-BEHAVIORAL AND VASCULAR/METABOLIC FACTORS) ASSOCIATED WITH THE AD/ADRD CONTINUUM; AND (AIM-3) DEVELOP AND VALIDATE A LONGITUDINAL MACHINE LEARNING NETWORK BY EMPLOYING HIGH-DIMENSIONAL DATA TO DISTINGUISH AD/ADRD RISK. WE WILL ACHIEVE THESE AIMS BY AUGMENTING THE COHORT WITH AD/ADRD PHENOTYPING AND GENOTYPING PROTOCOLS ALIGNED WITH THE NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTERS (P50 AG025688). THIS STUDY WILL FOCUS ON CHARACTERIZING RISKS AND OUTCOMES IN INDIVIDUALS WHO WERE ENROLLED IN P-CARRS IN TWO WAVES (2010, 2015) AT AGES ≥40 YEARS (N=8,142, 51% FEMALE, 78% LITERATE, 38% DIABETES, AND 48% HYPERTENSION). WE WILL CHARACTERIZE MIDDLE-LIFE AD/ADRD RISKS THROUGH NEWLY MEASURING: (A) USING BASELINE STORED SAMPLES (2010 OR 2015) TO PERFORM PLASMA AD/ ADRD BIOMARKERS (PTAU217, NFL, AND GFAP) AND WHOLE GENOME SEQUENCING AND (B) AT A NEW FOLLOW-UP EXAMINATION, ASSESS PLASMA AD BIOMARKERS AND ADMINISTER SENSITIVE AI-DRIVEN DIGITAL COGNITIVE MEASURES; AND C) ONLY IN THOSE >50 YEARS (N=4,132), WE WILL ADDITIONALLY OBTAIN COMPREHENSIVE COGNITIVE BATTERY, RETINAL, AND NEUROIMAGING. IN PRELIMINARY STUDIES, WE HAVE SUCCESSFULLY DEMONSTRATED THE FEASIBILITY OF ADMINISTERING NOVEL AI-ENABLED DIGITAL COGNITIVE ASSESSMENT TOOLS, COLLECTING AND PROCESSING PLASMA AD BIOMARKERS, AND PILOT STANDARDIZATION OF MRI NEUROIMAGING BIOMARKERS. THIS PROJECT WILL ADVANCE PROGRESS IN UNDERSTANDING THE NATURAL HISTORY OF THE AD/ADRD ALONG THE LIFE COURSE AND PROMOTE EARLY DETECTION, PRECISE DIAGNOSIS AND TAILORED THERAPEUTIC STRATEGIES FOR THIS HIGH-RISK, UNDERSTUDIED POPULATION AND BEYOND.
Department of Health and Human Services
$12.7M
EMORY HIV/AIDS CLINICAL TRIALS UNIT
Department of Health and Human Services
$12.6M
PD-1 FUNCTION, SIGNALING, AND REGULATION DURING VIRAL INFECTION
Department of Health and Human Services
$12.1M
BIOLOGICAL VARIATION IN HEMOPHILIA
Department of Health and Human Services
$12M
EMORY CENTER FOR INFECTIOUS DISEASE MODELING & ANALYTICS AND TRAINING HUB (CIDMATH)
Department of Health and Human Services
$11.7M
MORRIS K. UDALL CENTERS OF EXCELLENCE FOR PARKINSON'S DISEASE RESEARCH AT EMORY UNIVERSITY - PROJECT SUMMARY – OVERALL CENTER THE MORRIS K. UDALL PARKINSON'S DISEASE CENTER OF EXCELLENCE FOR PARKINSON’S DISEASE RESEARCH AT EMORY UNIVERSITY IS A COLLABORATIVE RESEARCH PROGRAM THAT STUDIES THE PATHOPHYSIOLOGY OF PARKINSONISM WITH THE GOAL OF OPTIMIZING THE TREATMENT FOR PARKINSON’S DISEASE (PD). THE CENTER DRAWS UPON THE PROVEN ABILITY OF THE BASAL GANGLIA RESEARCH COMMUNITY AT EMORY TO CONDUCT COLLABORATIVE TRANSLATIONAL RESEARCH. OTHER UDALL CENTER ASSETS ARE THE AVAILABILITY OF PRIMATES FOR RESEARCH AT THE YERKES NATIONAL PRIMATE RESEARCH CENTER AT EMORY, AND THE PRESENCE OF ONE OF THE LARGEST MOVEMENT DISORDERS CLINIC IN THE US. THE CENTER CONSISTS OF FOUR PROJECTS AND THREE CORES. THE PLANNED RESEARCH WILL SHED LIGHT ON THE POORLY UNDERSTOOD PARKINSONISM-RELATED ACTIVITY CHANGES OF SPECIFICALLY IDENTIFIED GROUPS OF PROJECTION NEURONS IN THE CEREBRAL CORTEX WHICH, IN TURN, WILL HELP US TO BETTER UNDERSTAND THE PATHOPHYSIOLOGY OF PARKINSONISM, AND TO OPTIMIZE THERAPEUTIC STRATEGIES. PROJECT 1 (LED BY DR. JAEGER) WILL UTILIZE RODENT EXPERIMENTS FOR LARGE-SCALE VOLTAGE IMAGING AND BRAIN SLICE RECORDINGS AND USE NEURAL COMPUTATIONAL APPROACHES TO DEVELOP MECHANISTIC MODELS OF CORTICAL DYSFUNCTION IN PARKINSONISM. PROJECT 2 (DR. GALVAN), WILL EXPLORE THE SPONTANEOUS AND TASK-RELATED ACTIVITY OF CORTICOSTRIATAL AND CORTICOSPINAL NEURONS IN THE PRIMARY MOTOR CORTEX (M1) AND THE SUPPLEMENTARY MOTOR AREA (SMA) IN NORMAL AND PARKINSONIAN MONKEYS, USING AN OPTO-TAGGING APPROACH TO IDENTIFY THE PROJECTION TARGETS OF THE RECORDED NEURONS. PROJECT 3 (DR. SMITH) WILL EXAMINE MORPHOLOGICAL CHANGES IN THE M1 AND SMA MICROCIRCUITRY AND PARKINSONISM-ASSOCIATED CHANGES IN THE CONNECTOME OF CORTICAL PROJECTION NEURONS IN PRIMATES, A TOPIC THAT IS VIRTUALLY UNEXPLORED AND OF HIGH RELEVANCE TO THE INTERPRETATION OF DATA IN PROJECTS 1 AND 2. THE CLINICAL ‘CATALYST’ PROJECT 4 IS AN EXAMINATION OF PARKINSONISM-RELATED CHANGES IN CORTICAL ACTIVITY IN RESPONSE INHIBITION TASKS, STUDIED IN ELECTROCORTICOGRAPHY AND ELECTROENCEPHALOGRAPHY SIGNALS IN PATIENTS WITH PD. THE FUNCTIONAL EXPERIMENTS WILL ALSO STUDY THE EFFECTS OF LEVODOPA AND DEEP BRAIN STIMULATION TREATMENTS IN THESE PARADIGMS. ALL PROJECTS WILL BE SUPPORTED BY AN ADMINISTRATIVE CORE (CORE A, DR. WICHMANN, PI; DR. SMITH, ASSOCIATE DIRECTOR, MS HOLBROOK, ADMINISTRATOR), AND BY A SERVICE CORE THAT PROVIDES ANATOMICAL SERVICES TO PROJECTS 1 AND 2, BEHAVIORAL ASSESSMENTS TO PROJECTS 2 AND 3, AND STATISTICAL SERVICES TO ALL PROJECTS (CORE B, DR. GALVAN). A CLINICAL CORE (CORE C) WILL SUPPORT PROJECT 4 WITH RECRUITMENT AND LOGISTIC SERVICES FOR THE HUMAN STUDIES. IN ADDITION TO PURSUING ITS RESEARCH MISSION (AIM 1), THE CENTER WILL HELP YOUNG SCIENTISTS TO DEVELOP THEIR CAREER IN PD RESEARCH (AIM 2), AND WILL ENGAGE IN EXTENSIVE OUTREACH EFFORTS, AIMED AT COMMUNICATING THE CENTER’S (AND UDALL CENTER NETWORK) RESEARCH FINDINGS TO THE PUBLIC (AIM 3), REACHING ALL AGE GROUPS AND BACKGROUND LEVELS. AS PART OF THE OUTREACH AGENDA, THE CENTER PLANS TO ORGANIZE ANNUAL OUTREACH EVENTS FOR PATIENTS AND THEIR CAREGIVERS. GENEROUS INTERNAL SUPPORT FUNDS WILL HELP THE CENTER TO FUND SOME OF ITS EDUCATION AND OUTREACH MISSIONS, AS WELL AS ITS PILOT GRANT PROGRAM, DESIGNED TO EXPAND PD RESEARCH AT EMORY.
Department of Health and Human Services
$11.6M
A HUMAN FACTORS APPROACH TO STRENGTHENING INFECTION PREVENTION AND CONTROL
Department of Health and Human Services
$11.5M
PRECISION CARDIOVASCULAR DISEASES PHENOTYPING AND PATHOPHYSIOLOGICAL PATHWAYS IN THE CARRS COHORT (PRECISION-CARRS) - PROJECT SUMMARY / ABSTRACT (OVERALL) PRECISION-CARRS WILL REVOLUTIONIZE THE CARDIOVASCULAR DISEASE (CVD) PREVENTION AND CARE PARADIGM FROM IMPRECISE PREDICTION WITH FOCUS ON LATE STAGE DISEASE TO PERSONALIZED AND PRECISE PREDICTION WITH IMPROVED UNDERSTANDING OF EARLY-STAGE DISEASE TO MAINTAIN CARDIOVASCULAR HEALTH. ATHEROSCLEROTIC CVD (ASCVD) AND HEART FAILURE (HF) PHENOTYPES ARE HETEROGENEOUS AND RESULT FROM COMPLEX INTERACTIONS BETWEEN IMMUTABLE GENETIC FACTORS AND MUTABLE FORCES OPERATING AT ENVIRONMENTAL (E.G., AMBIENT AIR QUALITY), INDIVIDUAL (E.G., HEALTH BEHAVIORS, SOCIAL INFLUENCE), AND MOLECULAR (E, G, PROTEINS, 'OMICS) LEVELS. SOUTH ASIANS ARE AN UNDERSTUDIED POPULATION AT HIGH CVD RISK EVEN AT YOUNG AGES, AT LOW BODY WEIGHT, AND IN THE ABSENCE OF TRADITIONAL RISK FACTORS. WE WILL LEVERAGE SUBSTANTIAL MATCHED RESOURCES, AND ALSO BUILD UPON THE NHLBI- FUNDED CARRS COHORT, A REPRESENTATIVE SAMPLE OF N=21,864 SOUTH ASIANS AGED = 20 YEARS, WITH ONGOING FOLLOW-UP FOR CLINICAL ASCVD RISK FACTORS, CLINICAL DISEASE, AND MORTALITY. THE COHORT HAS HIGH RETENTION (>95% HAVE AT LEAST ONE FOLLOW-UP) AND A BIOREPOSITORY OF 360,000 STORED SAMPLES. WE WILL ADD DETAILED SUBCLINICAL AND CLINICAL CVD PHENOTYPING, REPEATED MEASURES OF TARGETED PROTEIN MARKERS AND UNTARGETED MULTI-OMICS, AND REAL-TIME ASSESSMENT OF HEALTH BEHAVIORS. BY EXTENDING FOLLOW-UP BY AN ADDITIONAL 5 YEARS, WE WILL ACCRUE 176,536 PERSON-YEARS OF FOLLOW UP, >1,000 INCIDENT ASCVD, AND NEARLY >900 CASES OF CLINICAL HF (STAGES C/D). ENABLED BY PRECISE MAPPING OF CVD AT THE GRANULAR LEVEL OF SUBCLINICAL AND CLINICAL PHENOTYPES, WE WILL INVESTIGATE THE EPIDEMIOLOGY AND CAUSES OF CVD ALONG BOTH ASCVD AND HF PATHWAYS. THREE COMPLEMENTARY CORES (ADMINISTRATIVE AND FIELD COORDINATION; CVD PHENOTYPING; AND DATA MANAGEMENT AND ANALYSIS) WILL SUPPORT FOUR INTERCONNECTED PROJECTS, ONE OF WHICH IS LED BY AN EARLY-STAGE INVESTIGATOR (ESI). ALL FOUR PROJECT EXAMINE COMMON SUBCLINICAL AND CLINICAL ENDPOINTS FROM SYNERGISTIC VANTAGE POINTS: TRADITIONAL RISK FACTORS AND TARGETED PROTEIN-BASED PATHOPHYSIOLOGICAL PATHWAYS (PROJECT 1), THE IMPACT OF AIR POLLUTION AND MEDIATING MECHANISMS (PROJECT 2), MOLECULAR SIGNALS AND MECHANISMS THROUGH INTEGRATIVE UNTARGETED MULTI-OMICS (PROJECT 3), AND SOCIO-BEHAVIORAL INFLUENCES ON CVD RISK AND OUTCOMES STUDIED VIA SPOUSAL DYADS (PROJECT 4, ESI). PRECISION-CARRS WILL UNRAVEL THE NATURAL HISTORY, PATHOPHYSIOLOGY, AND CAUSAL FACTORS OF VASCULAR AND MYOCARDIAL DISEASE AND PAVE THE WAY FOR PRECISION CVD DIAGNOSTICS, PREVENTION, AND CARE FOR SOUTH ASIANS–WHO REPRESENT ONE FIFTH OF HUMANITY AND ARE A RAPIDLY GROWING SUB- POPULATION IN THE US. IN SUMMARY, PRECISION-CARRS IS DESIGNED TO BE A POWERFUL PLATFORM TO UNDERSTAND THE NATURAL HISTORY OF CVD IN AN UNDERSTUDIED HIGH-RISK POPULATION AND TO SPUR FUTURE INNOVATIVE SCIENTIFIC COLLABORATIONS WITH OTHER CVD LONGITUDINAL COHORTS IN THE US AND GLOBALLY.
Department of Health and Human Services
$11.4M
TARGETING MTOR AND CD40 PATHWAYS FOR ADJUVANTING HIV VACCINES
Department of Health and Human Services
$11.3M
EMORY-GSK-NIMH COLLABORATIVE MOOD DISORDERS INITIATIVE
Department of Health and Human Services
$11.1M
P30- CORE GRANT FOR VISION RESEARCH
Department of Health and Human Services
$11M
MENTAL STRESS ISCHEMIA: PROGNOSIS AND GENETIC INFLUENCES
Department of Health and Human Services
$10.8M
B CELLS IN HEALTH AND DISEASE
Department of Health and Human Services
$10.7M
EMORY SPECIALIZED CENTER OF RESEARCH EXCELLENCE (SCORE) ON SEX DIFFERENCES
Department of Health and Human Services
$10.7M
EMORY PREVENTION RESEARCH CENTER
Department of Health and Human Services
$10.6M
RAPID DEVELOPMENT AND DEPLOYMENT OF NON-PHYSICIAN PROVIDERS IN CRITICAL CARE
Department of Health and Human Services
$10.6M
HETERORESISTANCE INTERDISCIPLINARY RESEARCH UNIT - ABSTRACT ANTIBIOTIC RESISTANCE IS ONE OF THE MOST SERIOUS MEDICAL CHALLENGES OF OUR TIME. THIS CRISIS PUTS PATIENTS AT RISK OF UNTREATABLE BACTERIAL INFECTIONS AND THREATENS MAJOR ADVANCES OF MODERN MEDICINE THAT RELY ON ANTIBIOTICS (TRANSPLANTS, CHEMOTHERAPY, ETC). THERE ARE AT LEAST 2.8 MILLION ANTIBIOTIC RESISTANT INFECTIONS EACH YEAR IN THE US, LEADING TO OVER 35,000 DEATHS [1]. WITHOUT SIGNIFICANT ACTION, WORLDWIDE ANNUAL MORTALITY DUE TO THESE INFECTIONS IS PREDICTED TO REACH 10 MILLION BY 2050, SURPASSING THAT PREDICTED FOR CANCER [2]. UNDERSTANDING RESISTANCE MECHANISMS IS CRITICAL TO DESIGNING NOVEL APPROACHES AND THERAPEUTICS TO COMBAT RESISTANT BACTERIA. HETERORESISTANCE (HR) IS AN ENIGMATIC FORM OF ANTIBIOTIC RESISTANCE IN WHICH A BACTERIAL ISOLATE HARBORS A RESISTANT SUBPOPULATION THAT CAN RAPIDLY REPLICATE IN THE PRESENCE OF AN ANTIBIOTIC, WHILE A SUSCEPTIBLE SUBPOPULATION IS KILLED [3, 4]. NOT ONLY DO MANY SPECIES OF BACTERIA EXHIBIT THIS FORM OF PHENOTYPIC RESISTANCE, BUT IT HAS BEEN REPORTED AGAINST NEARLY ALL CLASSES OF ANTIBIOTICS [3, 5, 6]. UNFORTUNATELY, OUR UNDERSTANDING OF HR IS EXTREMELY LIMITED AND ITS RELEVANCE DURING INFECTION HAS BEEN UNCLEAR. WE RECENTLY DEMONSTRATED THAT HR TO DIVERSE ANTIBIOTICS, INCLUDING THE LAST-LINE ANTIBIOTIC COLISTIN, CAN CAUSE TREATMENT FAILURE IN AN IN VIVO MODEL [4, 5, 7]. FURTHERMORE, WHEN THE FREQUENCY OF THE RESISTANT SUBPOPULATION IS VERY LOW (<1 IN 10,000 CELLS) HR IS MISCLASSIFIED AS SUSCEPTIBLE BY CLINICAL DIAGNOSTIC TESTS, YET IS STILL ABLE TO MEDIATE TREATMENT FAILURE [4]. OUR SURVEILLANCE DATA REVEAL THAT HR TO DIVERSE CLASSES OF ANTIBIOTICS IS WIDESPREAD EVEN AMONG HIGHLY RESISTANT CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) AND ACINETOBACTER BAUMANNII (CRAB). FURTHER, WE RECENTLY DISCOVERED THAT TARGETING PAN-RESISTANT BACTERIA WITH TWO ANTIBIOTICS TO WHICH A STRAIN EXHIBITS HR RELIABLY LEADS TO EFFECTIVE COMBINATION THERAPY, HIGHLIGHTING THAT KNOWLEDGE OF HR CAN BE USED TO GUIDE EFFECTIVE THERAPIES [5]. TAKEN TOGETHER, THESE DATA HIGHLIGHT A LARGELY UNAPPRECIATED AND UNDETECTED EPIDEMIC OF HR IN THE CLINIC THAT MAY CAUSE UNEXPLAINED ANTIBIOTIC TREATMENT FAILURE BUT CAN ALSO BE EXPLOITED THERAPEUTICALLY. THE HETERORESISTANCE INTERDISCIPLINARY RESEARCH UNIT (HR-IRU) BRINGS TOGETHER AN INTERDISCIPLINARY TEAM OF EXPERTS IN AN UNPRECEDENTED EFFORT TO UNDERSTAND THE MECHANISMS, DYNAMICS, AND PREVALENCE OF HR. THE PROPOSED PROJECTS, SUPPORTED BY CLINICAL ISOLATE AND SINGLE-CELL ANALYSIS CORES, WILL USE A COMBINATION OF GENETICS, SINGLE CELL MICROSCOPY, DYNAMIC FLOW AND IN VIVO INFECTION STUDIES, MODELING, AND EPIDEMIOLOGICAL ANALYSES TO MAKE FOUNDATIONAL INSIGHTS INTO HR. AT A BASIC LEVEL, THIS WORK WILL SIGNIFICANTLY BROADEN OUR UNDERSTANDING OF HOW TRAITS EXHIBITED BY SUBPOPULATIONS OF CELLS CAN IMPACT BACTERIAL PHYSIOLOGY. AT A TRANSLATIONAL LEVEL, THIS EFFORT WILL BE A CRITICAL STEP IN OUR FIGHT AGAINST ANTIBIOTIC RESISTANT BACTERIA AND LAY THE FOUNDATION FOR THE DISCOVERY OF NOVEL THERAPEUTICS, DIAGNOSTICS, AND APPROACHES TO ALLEVIATE HUMAN SUFFERING.
Department of Health and Human Services
$10.3M
GENE DISCOVERIES IN SUBJECTS WITH CROHN'S DISEASE OF AFRICAN DESCENT
Department of Health and Human Services
$10.3M
SPINAL CIRCUITS AND THE MUSCULOSKELETAL SYSTEM
Department of Health and Human Services
$10.2M
CD40L ADJUVANTED CLADE C DNA AND MVA HIV VACCINES
Department of Health and Human Services
$10.2M
PRESERVING RENAL FUNCTION & PROTECTIVE IMMUNITY VIA ANTI-LFA1-BASED CNI AVOIDANCE
Department of Health and Human Services
$10.1M
EMORY UNIVERSITY LUNG CANCER SPORE
Department of Health and Human Services
$10M
SOUTHERN REGIONAL DISASTER RESPONSE SYSTEM (SRDRS)
Department of Defense
$10M
MOLECULAR LEVEL STUDIES OF SOLID-LIQUID INTERFACES IN ELECTROCHEMICAL PROCESSES
Department of Defense
$9.8M
ADDITIONAL EFFORT FOR DARPA GRANT ENTITLED, "DEVELOPMENT OF ANTIBODIES THERAPEUTICS AGAINST EBOLA"
Department of Health and Human Services
$9.7M
SPORE IN HEAD AND NECK CANCER
Department of Health and Human Services
$9.7M
REGIONAL EMERGING SPECIAL PATHOGEN TREATMENT CENTER EMORY UNIVERSITY AND CHILDRENS HEALTHCARE OF ATLANTA - THE PURPOSE OF THIS PROPOSAL IS FOR THE AWARDEE, EMORY UNIVERSITY IN COLLABORATION WITH CHILDREN’S HEALTHCARE OF ATLANTA-EGLESTON, TO SUPPORT HHS ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE BY MAINTAINING AN EMERGING SPECIAL PATHOGENS TREATMENT CENTER (RESPTC) FOR REGION 4. THE BIOCONTAINMENT UNIT AT EMORY UNIVERSITY HOSPITAL IS SUPPORTED BY ALL OF EMORY HEALTHCARE IN PARTNERSHIP WITH EMORY UNIVERSITY. THE EXPECTED OUTCOMES OF THIS PROJECT ARE TO: - SERVE AS REGIONAL LEADERS IN DEVELOPING, DISSEMINATING, AND MAINTAINING STANDARDS, GUIDANCE, AND PROMISING PRACTICES FOR HIGH-QUALITY, COORDINATED SPECIAL PATHOGEN CARE AND FOR DECISION-MAKING DURING A SPECIAL PATHOGEN OUTBREAK. - BUILD CAPACITY FOR THE NATIONAL SPECIAL PATHOGEN SYSTEM (NSPS) TO ACCELERATE SPECIAL PATHOGEN RESEARCH, SERVING AS A REGIONAL HUB TO CONDUCT, PARTICIPATE IN, AND SHARE INSIGHTS RELATED TO SPECIAL PATHOGEN AND CLINICAL TRIAL RESEARCH. - MAINTAIN A TRAINED, DIVERSE, AND SPECIALIZED WORKFORCE ACROSS THEIR REGION AND THE NSPS, SERVE AS A REGIONAL LEADER IN PROVIDING SPECIAL PATHOGEN TRAININGS, EXPLORE INNOVATIVE AND FLEXIBLE HEALTH CARE WORKFORCE SOLUTIONS, AND SHARE RESOURCES AND PROMISING PRACTICES TO DEVELOP AND MAINTAIN WORKFORCE CAPABILITIES TO RESPOND TO SPECIAL PATHOGENS SURGE EVENTS. AS THE FIRST BIOCONTAINMENT UNIT IN THE US, THE FIRST HOSPITAL TO CARE FOR PATIENTS WITH EBOLA, ONE OF THE LEADING INSTITUTIONS FOR THE NATIONAL EMERGING SPECIAL PATHOGENS TRAINING AND EDUCATION CENTER, AND A DESIGNATED RESPTC SINCE 2015, EMORY IS WELL POSITIONED TO REMAIN THE REGION IV RESPTC. IN ADDITION TO THE RESPTC ASSETS CURATED SINCE THE CREATION OF THE SERIOUS COMMUNICABLE DISEASES UNIT, EMORY ALSO SERVES AS THE SOUTHEASTERN REGIONAL DISASTER HEALTH RESPONSE SYSTEM.
Department of Health and Human Services
$9.6M
?RESETTING IMMUNE HOMEOSTASIS: A NON-INVASIVE APPROACH TOWARDS HIV ERADICATION
Department of Health and Human Services
$9.5M
EVOLUTION OF AGING AND DEMENTIA IN FEMALE PRIMATES
Department of Health and Human Services
$9.4M
IMMUNE REGULATION OF COVID-19 INFECTION IN CANCER AND AUTOIMMUNITY
Department of Health and Human Services
$9.3M
4/24 HEALTHY BRAIN AND CHILD DEVELOPMENT NATIONAL CONSORTIUM - PROJECT SUMMARY/ABSTRACT NEURODEVELOPMENTAL PROCESSES ARE SHAPED BY DYNAMIC INTERACTIONS BETWEEN GENES AND ENVIRONMENTS. MALADAPTIVE EXPERIENCES EARLY IN LIFE CAN ALTER DEVELOPMENTAL TRAJECTORIES, LEADING TO HARMFUL AND ENDURING DEVELOPMENTAL SEQUELAE. PRE- AND POSTNATAL HAZARDS INCLUDE MATERNAL SUBSTANCE EXPOSURE, TOXICANT EXPOSURES IN PREGNANCY AND EARLY LIFE, MATERNAL HEALTH CONDITIONS, PARENTAL PSYCHOPATHOLOGY, MALTREATMENT, STRUCTURAL RACISM, AND EXCESSIVE STRESS. TO ELUCIDATE HOW VARIOUS ENVIRONMENTAL HAZARDS IMPACT CHILD DEVELOPMENT, IT IS IMPERATIVE THAT A NORMATIVE TEMPLATE OF DEVELOPMENTAL TRAJECTORIES OVER THE FIRST 10 YEARS OF LIFE BE ESTABLISHED BASED ON A SUFFICIENTLY LARGE AND DEMOGRAPHICALLY DIVERSE SAMPLE OF THE US POPULATION. TO ACCOMPLISH THIS, THE HEALTHY BRAIN AND CHILD DEVELOPMENT NATIONAL CONSORTIUM (HBCD-NC) HAS BEEN FORMED TO DEPLOY A HARMONIZED, OPTIMIZED, AND INNOVATIVE SET OF NEUROIMAGING (MRI, EEG) MEASURES COMPLEMENTED BY AN EXTENSIVE BATTERY OF BEHAVIORAL, PHYSIOLOGICAL, AND PSYCHOLOGICAL TOOLS, AND BIOSPECIMENS TO UNDERSTAND NEURODEVELOPMENTAL TRAJECTORIES IN A SAMPLE OF 7,500 MOTHERS AND INFANTS ENROLLED AT 24 SITES ACROSS THE UNITED STATES (US). THE HBCD-NC WILL CARRY OUT A COMMON RESEARCH PROTOCOL UNDER DIRECTION OF THE HBCD-NC ADMINISTRATIVE CORE (HCAC) AND WILL ASSEMBLE AND DISTRIBUTE A COMPREHENSIVE AND WELL-CURATED RESEARCH DATASET TO THE SCIENTIFIC COMMUNITY AT LARGE UNDER THE DIRECTION OF THE HBCD-NC DATA COORDINATING CENTER (HDCC). THE OVERARCHING GOAL OF THE HBCD-NC IS TO CREATE A COMPREHENSIVE, HARMONIZED, AND HIGH- DIMENSIONAL DATASET THAT WILL CHARACTERIZE TYPICAL NEURODEVELOPMENTAL TRAJECTORIES IN US CHILDREN AND THAT WILL ASSESS HOW BIOLOGICAL AND ENVIRONMENTAL EXPOSURES AFFECT THOSE TRAJECTORIES. A SPECIAL EMPHASIS WILL BE PLACED ON UNDERSTANDING THE IMPACT OF PRE- AND POSTNATAL EXPOSURE TO OPIOIDS, MARIJUANA, ALCOHOL, TOBACCO AND/OR OTHER SUBSTANCES. TO ADDRESS THESE BROAD OBJECTIVES, THE SAMPLE OF WOMEN ENROLLED WILL INCLUDE: 1) A RACIALLY, ETHNICALLY, AND SOCIOECONOMICALLY DIVERSE COHORT THAT IS REPRESENTATIVE OF THE US POPULATION; 2) PREGNANT WOMEN WITH USE OF TARGETED SUBSTANCES (OPIOIDS, MARIJUANA, ALCOHOL, TOBACCO); AND 3) DEMOGRAPHICALLY AND BEHAVIORALLY SIMILAR WOMEN WITHOUT SUBSTANCE USE IN PREGNANCY TO ENABLE VALID CAUSAL INFERENCES. IN ADDITION, THE HBCD-NC WILL IDENTIFY KEY DEVELOPMENTAL WINDOWS DURING WHICH BOTH HARMFUL AND PROTECTIVE ENVIRONMENTS HAVE THE MOST INFLUENCE ON LATER NEURODEVELOPMENTAL OUTCOMES. THE LARGE, MULTI-MODAL, LONGITUDINAL, AND GENERALIZABLE DATASET THAT WILL BE PRODUCED FOR THE FIRST TIME BY THIS STUDY WILL PROVIDE NOVEL INSIGHTS INTO CHILD DEVELOPMENT USING STATE- OF-THE-ART METHODS. THE HBCD-NC STUDY WILL INFORM PUBLIC POLICY TO IMPROVE THE HEALTH AND DEVELOPMENT OF CHILDREN ACROSS THE NATION.
National Science Foundation
$9.3M
EXPANDING THE NORDP CONSULTANTS PROGRAM TO SIXTEEN MINORITY SERVING INSTITUTIONS -THE NSF GROWING RESEARCH ACCESS FOR NATIONALLY TRANSFORMATIVE EQUITY AND DIVERSITY (GRANTED) INITIATIVE SEEKS TO SUPPORT THE DEVELOPMENT OF THE RESEARCH SUPPORT AND SERVICE INFRASTRUCTURE TO ADDRESS THE COMPLEXITY OF SECURING AND MANAGING EXTERNAL FUNDING, PARTICULARLY AT EMERGING RESEARCH AND MINORITY SERVING INSTITUTIONS (ERIS AND MSIS). THIS PROJECT FROM THE NATIONAL ORGANIZATION OF RESEARCH DEVELOPMENT PROFESSIONAL (NORDP) EXPANDS ON PRIOR SUCCESSFUL EFFORTS WORKING WITH HISTORICALLY BLACK COLLEGES AND UNIVERSITIES AND FOCUSES ON PROVIDING FUNDAMENTAL RESEARCH DEVELOPMENT RESOURCES. RESEARCH DEVELOPMENT REFERS TO STRATEGIC, CATALYTIC, AND CAPACITY-BUILDING ACTIVITIES THAT ADVANCE RESEARCH. THIS PROJECT TESTS HOW THE DIVERSITY OF THE U.S. NATIONAL RESEARCH ECOSYSTEM CAN BE ENHANCED BY PROVIDING RESEARCH DEVELOPMENT SERVICES TO MSIS. IN THIS PROJECT, THE NORDP CONSULTANTS PROGRAM WILL EXTEND SUPPORT TO 16 MINORITY SERVING INSTITUTIONS ACROSS FOUR NEW COHORTS OF FOUR MSIS EACH. EACH SCHOOL WILL RECEIVE 600 HOURS OF CONSULTING TIME FROM EXPERIENCED NORDP CONSULTANTS OVER TWO YEARS AND GAIN ACCESS TO AN ARRAY OF OTHER RESEARCH DEVELOPMENT SUPPORTS FOR THE DURATION OF THE PROJECT PERIOD. THE PROGRAM WILL ALSO PROMOTE NETWORK CREATION AMONG THE INSTITUTIONS SELECTED, THROUGH COHORT COMMUNITY BUILDING EVENTS AND PARTICIPATION IN AN ANNUAL NATIONAL CONFERENCE. FORMATIVE AND SUMMATIVE EVALUATION ACTIVITIES ARE INCLUDED TO ASSESS THE EFFECTIVENESS OF THE APPROACH. THE PROJECT REPRESENTS AN INNOVATIVE, NOVEL, AND POTENTIALLY TRANSFORMATIVE MODEL OF HOW PROFESSIONAL SOCIETIES CAN WORK WITH ERIS AND MSIS, TO PROVIDE MORE EQUITABLE ACCESS TO RESOURCES THAT WILL INCREASE RESEARCH CAPACITY AND COMPETITIVENESS, ULTIMATELY STRENGTHENING THE NATION?S RESEARCH ENTERPRISE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.
Department of Health and Human Services
$9.2M
VIROLOGIC CORRELATES OF HETEROSEXUAL TRANSMISSION
Department of Health and Human Services
$9.2M
TARGETING PD-1 PATHWAY FOR FUNCTIONAL CURE OF AIDS
Department of Health and Human Services
$9.1M
POPULATION-BASED SURVEY OF SARS-COV-2 INFECTION AND IMMUNE RESPONSE
Department of Health and Human Services
$9.1M
MODIFIERS OF FMR1-ASSOCIATED DISORDERS: APPLICATION OF HIGH THROUGHPUT TECHNOLOGI
Department of Health and Human Services
$9M
CELLULAR AND MOLECULAR MECHANISMS OF ACUTE LUNG INJURY IN SICKLE CELL DISEASE
Department of Health and Human Services
$9M
EMORY ALCOHOL AND LUNG BIOLOGY CENTER
Department of the Interior
$8.9M
NONDESTRUCTIVE DIRECT DIGITAL CAPTURE OF HISTOPATHOLOGY WITH MINIMAL PROCESSING (MINUTES) COMBINED WITH A DEDICATED AI IMAGE ANALYSIS SYSTEM CAN REDUCE CURRENT RATES OF LUMPECTOMY POSITIVE MARGINS REQUIRING A SECOND SURGERY TO REEXCISE INVOLVED TISSUES FROM 25% OR MORE TO NEARLY ZERO. IN PANCREATIC RESECTIONS RATES OF DISCREPANCY AND OR DEFERRAL TO PERMANENT SECTIONS OF 10% OR MORE CAN BE REDUCED TO NEARLY ZERO BUT IMPORTANTLY ALSO WITH A CONCOMITANT DECREASE IN THE DIAGNOSTIC DIFFICULTY AND NEED FOR THE MOST HIGHLY EXPERT PATHOLOGISTS. BY THE END OF THE PROPOSED PROJECT WE WILL HAVE A FUNCTIONAL PROTOTYPE SYSTEM MARGINCALL WHICH WILL BE ABLE TO IMAGE SPECIMEN CONTOURS MARK SURGICAL RESECTION MARGINS SERIALLY CROSS SECTION TISSUE FIBI IMAGE SERIAL TISSUE SLICES PATHOLOGY IMAGE AI MAP CANCER (AND OR IN SITU NEOPLASIAS) TO EACH SLICE OF TISSUE ASSESS PROXIMITIES TO ALL MARGINS RECONSTRUCT A 3D ORIENTATION OF THE SERIAL SLICES AND HEAT MAP THE TUMOR PROXIMITY OVER THE SURFACE OF THE SPECIMEN CONTOUR IMAGE. THIS WILL PROVIDE THE SURGEON WITH PRECISE AREAS OF INVOLVEMENT AS WELL AS AREAS THAT ARE CLOSE AND WILL DISTINGUISH AREAS OF INVASIVE EXTENSION FROM AREAS OF IN SITU INVOLVEMENT OF THE GLANDS. IMPORTANTLY EXCISION OF INVASIVE VERSUS IN SITU CAN REQUIRE A DIFFERENT APPROACH SURGICALLY WITH IN SITU DISEASE REQUIRING AN EXCISION OF THE GLAND TREE OR LOBE. MARGINCALL WILL BE ABLE TO ADDRESS THESE CHALLENGES AND FUNCTION AS AN INTRAOPERATIVE END TO END SOLUTION FOR ENHANCED VISUALIZATION OF SURGICAL MARGINS WITHOUT THE NEED FOR A PATHOLOGIST. UNIVERSITY OF CALIFORNIA DAVIS INDIANA UNIVERSITY AND EINDHOVEN UNIVERSITY OF TECHNOLOGY ARE SUBRECIPIENTS PARTICIPATING IN THIS PROJECT.
Department of Health and Human Services
$8.8M
GH14-1419: ADVANCING NATIONAL PUBLIC HEALTH INSTITUTES GLOBALLY
Department of Health and Human Services
$8.7M
ADVANCING NATIONAL PUBLIC HEALTH INSTITUTES GLOBALLY TO STRENGTHEN PUBLIC HEALTH SYSTEMS TO ENABLE BETTER PREVENTION, DETECTION, AND RESPONDTO PUBLIC HEALTH THREATS.
Department of Health and Human Services
$8.7M
ANTIVIRAL ROLE OF CD8+ T CELLS IN ART-TREATED SIV-INFECTED MACAQUES
Department of Health and Human Services
$8.6M
DECIPHERING LKB1-ASSOCIATED IMMUNOTHERAPY RESISTANCE IN LUNG ADENOCARCINOMA (LUAD) - SUMMARY LUNG CANCER IS THE LEADING CANCER KILLER IN THE UNITED STATES. OUR TEAM PROPOSES TO DEVELOP NOVEL PERSONALIZED THERAPEUTIC STRATEGIES BY EXPLOITING VULNERABILITIES AND OPPORTUNITIES CREATED BY ALTERATIONS IN TUMOR SUPPRESSORS IN LUNG CANCER. SPECIFICALLY, WE FOCUS ON THE TUMOR SUPPRESSOR LKB1, WHICH IS ONE OF THE MOST COMMONLY MUTATED GENES IN LUNG ADENOCARCINOMA (LUAD); LKB1 MUTATIONS ARE DETECTED IN 15-25% OF LUAD, REPRESENTING A MAJOR SUBPOPULATION OF LUNG CANCER PATIENTS. DESPITE THE FREQUENCY, UPWARD TRAJECTORY OF INCIDENCE, AND AGGRESSIVE NATURE OF DISEASE, PATIENTS WITH LKB1-MUTANT LUAD NOT ONLY HAVE NO TARGETED THERAPEUTICS AVAILABLE, BUT ALSO SHOW POOR RESPONSE TO IMMUNE CHECKPOINT INHIBITORS, DEMANDING URGENT DEVELOPMENT OF EFFECTIVE THERAPEUTIC OPTIONS. TO ADDRESS THIS CRITICAL GAP, OUR REVISED APPLICATION WILL CAPITALIZE ON OUR INTEGRATED UNDERSTANDING OF LKB1-LOSS–EVOKED TUMOR GROWTH REGULATORY MECHANISMS AND SUPPRESSION OF ANTICANCER IMMUNITY TO DEVELOP INNOVATIVE CLINICAL APPROACHES FOR THE TREATMENT OF PATIENTS WITH LKB1-MUTANT LUAD. NEW PRELIMINARY DATA FROM OUR TEAM SHOWED THAT 1) LKB1 LOSS ALLOWS METABOLIC DYSREGULATION, SUCH AS GLUTAMATE DEHYDROGENASE (GDH) ACTIVATION BY FAK, LEADING TO INCREASED REGULATORY T CELLS AND IMMUNE SUPPRESSION; 2) LKB1-LOSS-TRIGGERED INHIBITION OF STING, A KEY INNATE IMMUNITY REGULATOR, CAN BE REVERSED BY AN IAP INHIBITOR, LEADING TO REACTIVATED IMMUNE RESPONSE AND ITS POTENT IN VIVO IMMUNE-DEPENDENT ANTICANCER EFFECT; AND 3) FAK IS ACTIVATED IN LKB1- DEFICIENT CANCER CELLS AND SUPPORTS CELL INVASION AND INHIBITS IMMUNE INFILTRATION. THESE RESULTS LEAD TO OUR CENTRAL HYPOTHESIS THAT MUTATED LKB1 MAY EXERT ITS IMMUNE SUPPRESSION FUNCTION THROUGH A DYSREGULATED ANTI-CANCER IMMUNITY CYCLE MEDIATED BY KEY METABOLIC, INNATE IMMUNITY, AND STROMAL REGULATORY FACTORS. TARGETING THESE FACTORS MAY LEAD TO NOVEL APPROACHES TO RE-ACTIVATE ANTICANCER IMMUNITY FOR EFFECTIVE THERAPEUTIC DEVELOPMENT IN LUAD. WE WILL ADDRESS THIS HYPOTHESIS THROUGH THREE HIGHLY INTEGRATED PROJECTS. PROJECT 1 WILL EXAMINE THE ROLE OF THE FAK-GDH1 AXIS IN IMMUNOTHERAPY RESISTANCE AND TUMOR PROGRESSION OF LKB1-MUTANT LUAD. PROJECT 2 WILL EXPLOIT OUR RECENTLY DISCOVERED LKB1-REGULATED IAP-JAK-STING SIGNALING IN LUAD TO REVERSE IMMUNE SUPPRESSION WITH AN IAP INHIBITOR TO ENHANCE IMMUNOTHERAPY EFFECT. PROJECT 3 WILL FOCUS ON TARGETING FAK- MEDIATED PRIMARY TUMOR PROGRESSION IN LKB1-MUTANT LUAD BY PERFORMING A CLINICAL TRIAL WITH THE COMBINATION OF A FAK INHIBITOR AND AN IMMUNE CHECKPOINT INHIBITOR COUPLED WITH MECHANISTIC STUDIES. THE PROJECTS ARE SUPPORTED BY THREE CORES, WHOSE FUNCTIONS ARE ADMINISTRATIVE (CORE 1), MOLECULAR PATHOLOGY AND IMMUNOLOGY (CORE 2), AND BIOINFORMATICS AND BIOSTATISTICS (CORE 3). THIS HIGHLY INTEGRATED EFFORT BUILDS ON NEW DISCOVERIES FROM OUR ESTABLISHED LUNG CANCER TEAM WITH MORE THAN 100 CO-PUBLICATIONS AND WITH STRONG INSTITUTIONAL SUPPORT. WE EXPECT TO ADVANCE LUNG CANCER TREATMENT STRATEGIES BY NEW AGENT DISCOVERY (GDH1 INHIBITORS), NEW APPLICATION OF CLINICAL STAGE IAP INHIBITORS, AND A NEW PHASE II CLINICAL TRIAL OF A FAK-TARGETED COMBINATION APPROACH TO OVERCOME IMMUNOTHERAPY RESISTANCE OF LKB1-MUTANT LUAD AND BRING TREATMENT OPTIONS TO THIS PATIENT POPULATION.
Source: Federal Audit Clearinghouse (fac.gov)
Years audited
10
Clean years
10
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditurecombined across all audits filed that year | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $1B | Yes | 2026-04-30 |
| 2024 | Clean | Unmodified (Clean) | $962.1M | Yes | 2025-05-22 |
| 2023 | Clean | Unmodified (Clean) | $932.9M | Yes | 2024-03-19 |
| 2022 | Clean | Unmodified (Clean) | $888.8M | Yes | 2023-04-10 |
| 2021 | Clean | Unmodified (Clean) | $916.1M | Yes | 2022-05-22 |
| 2020 | Clean | Unmodified (Clean) | $651.2M | Yes | 2021-07-28 |
| 2019 | Clean | Unmodified (Clean) | $614.9M | Yes | 2020-03-17 |
| 2018 | Clean | Unmodified (Clean) | $587.4M | Yes | 2019-04-16 |
| 2017 | Clean | Unmodified (Clean) | $558.4M | Yes | 2018-03-14 |
| 2016 | Clean | Unmodified (Clean) | $546.6M | Yes | 2017-04-05 |
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$1B
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$962.1M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$932.9M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$888.8M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$916.1M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$651.2M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$614.9M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$587.4M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$558.4M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$546.6M
Tax Year 2024 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: GROUP
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $7.3B | $1.2B | $6.6B | $22.2B | $16B |
| 2022IRS e-File | $6.3B | $1.1B | $6B | $20.9B | $14.7B |
| 2021 | $5.5B | $1.1B | $5B | $20.3B | $14.6B |
| 2020 | $4.8B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Ravi Thadhani Md Mph | See Schedule J, Part Iii | 65 | $5.1M | $640K | $66.6K | $5.8M |
| Srinivas Pulavarti | Vp-chief Investment Officer | 60 | $3.2M | $0 | $51.3K | $3.3M |
| Christopher Augostini | See Schedule J, Part Iii | 65 | $2.8M | $0 | $359K | $3.2M |
| Joon S Lee Md | Ceo, Emory Healthcare | 35 | $0 | $2.5M | $320.9K | $2.8M |
| Gregory Fenves | President | 80 | $1.9M | $0 | $567.3K | $2.4M |
| Ravi Bellamkonda | Provost/exec Vp, Acad Affairs | 65 | $1.1M | $0 | $201.5K | $1.3M |
| Allison Dykes Johnson | VP - University Secretary | 60 | $947.8K | $0 | $70.7K | $1M |
| Amy Adelman | Interim SVP General Counsel | 65 | $658.5K | $0 | $51K | $709.6K |
| Belva White | VP Of Finance And Treasury | 60 | $496.3K | $0 | $63.2K | $559.6K |
| John Ellis | Interim Chief Information Officer; Sr Vice Provost For Information Technology | 60 | $456.7K | $0 | $66.7K | $523.4K |
| Theresa Milazzo | VP - Human Resources | 60 | $423.8K | $0 | $43.8K | $467.7K |
| Delbridge King | VP - Human Resources | 60 | $410.3K | $0 | $55.7K | $466K |
| Brad Slutsky | SVP General Counsel | 60 | $0 | $0 | $0 | $0 |
| Pimolrat Thukral | VP Of Finance & Treasury; Deputy CFO | 60 | $0 | $0 | $0 | $0 |
Ravi Thadhani Md Mph
See Schedule J, Part Iii
$5.8M
Hrs/Wk
65
Compensation
$5.1M
Related Orgs
$640K
Other
$66.6K
Srinivas Pulavarti
Vp-chief Investment Officer
$3.3M
Hrs/Wk
60
Compensation
$3.2M
Related Orgs
$0
Other
$51.3K
Christopher Augostini
See Schedule J, Part Iii
$3.2M
Hrs/Wk
65
Compensation
$2.8M
Related Orgs
$0
Other
$359K
Joon S Lee Md
Ceo, Emory Healthcare
$2.8M
Hrs/Wk
35
Compensation
$0
Related Orgs
$2.5M
Other
$320.9K
Gregory Fenves
President
$2.4M
Hrs/Wk
80
Compensation
$1.9M
Related Orgs
$0
Other
$567.3K
Ravi Bellamkonda
Provost/exec Vp, Acad Affairs
$1.3M
Hrs/Wk
65
Compensation
$1.1M
Related Orgs
$0
Other
$201.5K
Allison Dykes Johnson
VP - University Secretary
$1M
Hrs/Wk
60
Compensation
$947.8K
Related Orgs
$0
Other
$70.7K
Amy Adelman
Interim SVP General Counsel
$709.6K
Hrs/Wk
65
Compensation
$658.5K
Related Orgs
$0
Other
$51K
Belva White
VP Of Finance And Treasury
$559.6K
Hrs/Wk
60
Compensation
$496.3K
Related Orgs
$0
Other
$63.2K
John Ellis
Interim Chief Information Officer; Sr Vice Provost For Information Technology
$523.4K
Hrs/Wk
60
Compensation
$456.7K
Related Orgs
$0
Other
$66.7K
Theresa Milazzo
VP - Human Resources
$467.7K
Hrs/Wk
60
Compensation
$423.8K
Related Orgs
$0
Other
$43.8K
Delbridge King
VP - Human Resources
$466K
Hrs/Wk
60
Compensation
$410.3K
Related Orgs
$0
Other
$55.7K
Brad Slutsky
SVP General Counsel
$0
Hrs/Wk
60
Compensation
$0
Related Orgs
$0
Other
$0
Pimolrat Thukral
VP Of Finance & Treasury; Deputy CFO
$0
Hrs/Wk
60
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Dane Peterson | Interim CEO - Ehc | 30 | $0 | $3.2M | $494.4K | $3.7M |
| John W Xerogeanes Md | Physician | — | $52 | $2.8M | $63K | $2.8M |
| Bryce Gartland Md | Hospital Group President Ehc | 35 | $0 | $2.5M |
Dane Peterson
Interim CEO - Ehc
$3.7M
Hrs/Wk
30
Compensation
$0
Related Orgs
$3.2M
Other
$494.4K
John W Xerogeanes Md
Physician
$2.8M
Hrs/Wk
—
Compensation
$52
Related Orgs
$2.8M
Other
$63K
Bryce Gartland Md
Hospital Group President Ehc
$2.8M
Hrs/Wk
35
Compensation
$0
Related Orgs
$2.5M
Other
$264.7K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Adam H Rogers | Trustee | 2 | $0 | $0 | $0 | $0 |
| Allegra Lawrence-Hardy | Trustee | 1 | $0 | $0 | $0 | $0 |
| Allison Dukes | Trustee | 1 | $0 | $0 | $0 | $0 |
| Andrew W Evans | Trustee | 2 | $0 | $0 | $0 | $0 |
| Crystal Edmonson | Trustee | 3 | $0 | $0 | $0 | $0 |
| Cynthia M Sanborn | Trustee |
Adam H Rogers
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Allegra Lawrence-Hardy
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Allison Dukes
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Jonathan S Lewin Md | Former Officer | 40 | $837.7K | $875.1K | $310.2K | $2M |
| David Stephens Md | Former Interim Evpha | 40 | $643.6K | $504.8K | $40.4K | $1.2M |
| Jan Love | Former Officer | 60 | $468.1K | $0 |
Jonathan S Lewin Md
Former Officer
$2M
Hrs/Wk
40
Compensation
$837.7K
Related Orgs
$875.1K
Other
$310.2K
David Stephens Md
Former Interim Evpha
$1.2M
Hrs/Wk
40
Compensation
$643.6K
Related Orgs
$504.8K
Other
$40.4K
Jan Love
Former Officer
$511.8K
Hrs/Wk
60
Compensation
$468.1K
Related Orgs
$0
Other
$43.7K
| $838.6M |
| $4.6B |
| $16.8B |
| $11.5B |
| 2019 | $4.7B | $850.7M | $4.4B | $14.8B | $10.6B |
| 2018 | $4.5B | $1.1B | $4B | $14.2B | $10B |
| 2017 | $4.1B | $717.2M | $3.7B | $13.2B | $9B |
| 2016 | $3.6B | $640M | $3.5B | $12.3B | $8.2B |
| 2015 | $3.5B | $585.3M | $3.3B | $11.9B | $8B |
| 2014 | $3.5B | $626.7M | $3.1B | $12.2B | $8.4B |
| 2013 | $3.3B | $709.9M | $3B | $11B | $7.5B |
| 2012 | $3.1B | $650.2M | $2.9B | $10.4B | $6.8B |
| 2011 | $3.1B | $597.6M | $2.8B | $9.8B | $6.5B |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $264.7K |
| $2.8M |
| Faiz U Ahmad Md | Physician | — | $409K | $2.2M | $76.8K | $2.6M |
| Alistair Erskine Md Mbafamia | Chief Information And Digital Officer (ehc) | 30 | $2.2M | $215K | $239.1K | $2.6M |
| Shervin Oskouei Md | Physician | — | $28 | $2.3M | $62.8K | $2.4M |
| Paul J Chai Md | Physician | — | $0 | $2.2M | $49.9K | $2.2M |
| Daniel Owens | CEO - Emory University Hospital Midtown | 60 | $1.5M | $230.4K | $401.2K | $2.1M |
| John M Rhee Md | Physician | — | $52 | $1.9M | $61.8K | $2M |
| Bradley Haws | CFO Emory Healthcare | 30 | $0 | $1.6M | $47.5K | $1.7M |
| William Bornstein Md | Cmo & Cqpso (ehc) | 30 | $0 | $1.3M | $168.7K | $1.5M |
| Matt Wain | President Ehc Univ Hosp Div | 30 | $720.2K | $285.5K | $205.6K | $1.2M |
| Carlos Del Rio Md | Interim Dean, School Of Medicine | 60 | $985.3K | $24.5K | $42.7K | $1.1M |
| Patrick Hammond | Chief Market Services Officer, Ehc | 30 | $0 | $868.9K | $155.9K | $1M |
| Vikas Sukhatme Md | Dean, School Of Medicine | 45 | $727.1K | $226.7K | $63.3K | $1M |
| Joshua R Newton | SVP - Adv. & Alum. Engagement | 65 | $825.5K | $0 | $173.5K | $999K |
| Sharon Pappas | Chief Nursing Officer - Ehc | 30 | $0 | $728.4K | $122.5K | $850.8K |
| Heather Hamby | Cbo, Som/asc Vp, Clin Intgrtn | 60 | $295.1K | $473.7K | $54.9K | $823.6K |
| Rochester Anderson Jr | Chief Hr Officer (ehc) | 30 | $0 | $692.3K | $122.8K | $815.1K |
| Adam C Webb Md | COO Euhm | 60 | $423.2K | $143.4K | $157.4K | $724.1K |
| Carla Chandler | Hospital Group VP & CFO (ehc) | 30 | $0 | $657.4K | $20.8K | $678.2K |
| Lilicia Bailey | Chief Hr Officer (ehc) | 30 | $0 | $476.6K | $132.8K | $609.5K |
| Deborah Bruner | SVP Research | 60 | $525.5K | $0 | $55.9K | $581.4K |
| Enku Gelaye | SVP -dean Of Campus Life | 60 | $504.5K | $0 | $65.5K | $570K |
| Carla Freeman | Interim Dean - Emory College | 45 | $496.8K | $0 | $51.9K | $548.7K |
Faiz U Ahmad Md
Physician
$2.6M
Hrs/Wk
—
Compensation
$409K
Related Orgs
$2.2M
Other
$76.8K
Alistair Erskine Md Mbafamia
Chief Information And Digital Officer (ehc)
$2.6M
Hrs/Wk
30
Compensation
$2.2M
Related Orgs
$215K
Other
$239.1K
Shervin Oskouei Md
Physician
$2.4M
Hrs/Wk
—
Compensation
$28
Related Orgs
$2.3M
Other
$62.8K
Paul J Chai Md
Physician
$2.2M
Hrs/Wk
—
Compensation
$0
Related Orgs
$2.2M
Other
$49.9K
Daniel Owens
CEO - Emory University Hospital Midtown
$2.1M
Hrs/Wk
60
Compensation
$1.5M
Related Orgs
$230.4K
Other
$401.2K
John M Rhee Md
Physician
$2M
Hrs/Wk
—
Compensation
$52
Related Orgs
$1.9M
Other
$61.8K
Bradley Haws
CFO Emory Healthcare
$1.7M
Hrs/Wk
30
Compensation
$0
Related Orgs
$1.6M
Other
$47.5K
William Bornstein Md
Cmo & Cqpso (ehc)
$1.5M
Hrs/Wk
30
Compensation
$0
Related Orgs
$1.3M
Other
$168.7K
Matt Wain
President Ehc Univ Hosp Div
$1.2M
Hrs/Wk
30
Compensation
$720.2K
Related Orgs
$285.5K
Other
$205.6K
Carlos Del Rio Md
Interim Dean, School Of Medicine
$1.1M
Hrs/Wk
60
Compensation
$985.3K
Related Orgs
$24.5K
Other
$42.7K
Patrick Hammond
Chief Market Services Officer, Ehc
$1M
Hrs/Wk
30
Compensation
$0
Related Orgs
$868.9K
Other
$155.9K
Vikas Sukhatme Md
Dean, School Of Medicine
$1M
Hrs/Wk
45
Compensation
$727.1K
Related Orgs
$226.7K
Other
$63.3K
Joshua R Newton
SVP - Adv. & Alum. Engagement
$999K
Hrs/Wk
65
Compensation
$825.5K
Related Orgs
$0
Other
$173.5K
Sharon Pappas
Chief Nursing Officer - Ehc
$850.8K
Hrs/Wk
30
Compensation
$0
Related Orgs
$728.4K
Other
$122.5K
Heather Hamby
Cbo, Som/asc Vp, Clin Intgrtn
$823.6K
Hrs/Wk
60
Compensation
$295.1K
Related Orgs
$473.7K
Other
$54.9K
Rochester Anderson Jr
Chief Hr Officer (ehc)
$815.1K
Hrs/Wk
30
Compensation
$0
Related Orgs
$692.3K
Other
$122.8K
Adam C Webb Md
COO Euhm
$724.1K
Hrs/Wk
60
Compensation
$423.2K
Related Orgs
$143.4K
Other
$157.4K
Carla Chandler
Hospital Group VP & CFO (ehc)
$678.2K
Hrs/Wk
30
Compensation
$0
Related Orgs
$657.4K
Other
$20.8K
Lilicia Bailey
Chief Hr Officer (ehc)
$609.5K
Hrs/Wk
30
Compensation
$0
Related Orgs
$476.6K
Other
$132.8K
Deborah Bruner
SVP Research
$581.4K
Hrs/Wk
60
Compensation
$525.5K
Related Orgs
$0
Other
$55.9K
Enku Gelaye
SVP -dean Of Campus Life
$570K
Hrs/Wk
60
Compensation
$504.5K
Related Orgs
$0
Other
$65.5K
Carla Freeman
Interim Dean - Emory College
$548.7K
Hrs/Wk
45
Compensation
$496.8K
Related Orgs
$0
Other
$51.9K
| 3 |
| $0 |
| $0 |
| $0 |
| $0 |
| Darren W Cohen | Trustee | 1 | $0 | $0 | $0 | $0 |
| David Graves | Trustee | 1 | $6,667 | $0 | $0 | $6,667 |
| Deborah A Marlowe | Trustee | 2 | $0 | $0 | $0 | $0 |
| E Jenner Wood Iii | Trustee | 1 | $0 | $0 | $0 | $0 |
| Facundo L Bacardi | Trustee | 1 | $0 | $0 | $0 | $0 |
| Gregory J Vaughn | Trustee | 1 | $0 | $0 | $0 | $0 |
| Gregory V Palmer | Trustee | 1 | $0 | $0 | $0 | $0 |
| James Walker Burns | Trustee | 3 | $0 | $0 | $0 | $0 |
| Javier C Goizueta | Trustee | 2 | $0 | $0 | $0 | $0 |
| John G Rice | Trustee | 4 | $0 | $0 | $0 | $0 |
| John L Latham | Trustee | 1 | $0 | $0 | $0 | $0 |
| Jonathan K Layne | Trustee | 1 | $0 | $0 | $0 | $0 |
| Kathelen Amos | Trustee | 2 | $0 | $0 | $0 | $0 |
| L Jonathan Holston | Trustee | 1 | $0 | $0 | $0 | $0 |
| Leah Ward Sears | Trustee | 3 | $0 | $0 | $0 | $0 |
| Lee P Miller | Trustee | 2 | $0 | $0 | $0 | $0 |
| Mark A Weinberger | Trustee | 1 | $0 | $0 | $0 | $0 |
| Mitchell A Tanzman | Trustee | 3 | $0 | $0 | $0 | $0 |
| Muhtar Kent | Trustee | 1 | $0 | $0 | $0 | $0 |
| Rick M Rieder | Trustee | 1 | $0 | $0 | $0 | $0 |
| Robert C Goddard Iii | Trustee | 4 | $0 | $0 | $0 | $0 |
| Robin Dease | Trustee | 1 | $0 | $0 | $0 | $0 |
| Rosa Tarbutton Sumter | Trustee | 2 | $0 | $0 | $0 | $0 |
| Sarah B Brown | Trustee | 3 | $0 | $0 | $0 | $0 |
| Shantella Carr Cooper | Trustee | 2 | $0 | $0 | $0 | $0 |
| Stuart A Rose | Trustee | 2 | $0 | $0 | $0 | $0 |
| Sue Haupert-Johnson | Trustee | 1 | $0 | $0 | $0 | $0 |
| Tania Neild | Trustee | 1 | $0 | $0 | $0 | $0 |
| Tash Elwyn | Trustee | 1 | $0 | $0 | $0 | $0 |
| Teresa M Rivero | Trustee | 3 | $0 | $0 | $0 | $0 |
| Thomas I Barkin | Trustee | 3 | $0 | $0 | $0 | $0 |
| Timothy C Rollins | Trustee | 3 | $0 | $0 | $0 | $0 |
| William A Brosius | Trustee | 2 | $0 | $0 | $0 | $0 |
| William C Warren Iv | Trustee | 1 | $0 | $0 | $0 | $0 |
| William H Rogers Jr | Trustee | 2 | $0 | $0 | $0 | $0 |
| William T Mcalilly | Trustee | 1 | $0 | $0 | $0 | $0 |
Andrew W Evans
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Crystal Edmonson
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Cynthia M Sanborn
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Darren W Cohen
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
David Graves
Trustee
$6,667
Hrs/Wk
1
Compensation
$6,667
Related Orgs
$0
Other
$0
Deborah A Marlowe
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
E Jenner Wood Iii
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Facundo L Bacardi
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Gregory J Vaughn
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Gregory V Palmer
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
James Walker Burns
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Javier C Goizueta
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
John G Rice
Trustee
$0
Hrs/Wk
4
Compensation
$0
Related Orgs
$0
Other
$0
John L Latham
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Jonathan K Layne
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Kathelen Amos
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
L Jonathan Holston
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Leah Ward Sears
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Lee P Miller
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Mark A Weinberger
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Mitchell A Tanzman
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Muhtar Kent
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Rick M Rieder
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Robert C Goddard Iii
Trustee
$0
Hrs/Wk
4
Compensation
$0
Related Orgs
$0
Other
$0
Robin Dease
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Rosa Tarbutton Sumter
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Sarah B Brown
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Shantella Carr Cooper
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Stuart A Rose
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Sue Haupert-Johnson
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Tania Neild
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Tash Elwyn
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Teresa M Rivero
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Thomas I Barkin
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Timothy C Rollins
Trustee
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
William A Brosius
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
William C Warren Iv
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
William H Rogers Jr
Trustee
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
William T Mcalilly
Trustee
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
| $43.7K |
| $511.8K |
| Paul P Marthers | Former Officer | 45 | $399.6K | $0 | $64.3K | $464K |
| Greg Anderson | Former Key Employee | 60 | $337K | $44.7K | $68.4K | $450.1K |
| Liz Daunt-Samford | Former Key Employee | 60 | $339.8K | $45.9K | $47.2K | $432.9K |
| Claire Sterk | Former Officer | 40 | $365.6K | $0 | $42.4K | $408K |
| Sara Shockley | Former Key Employee | 20 | $0 | $364.6K | $39.3K | $403.9K |
| Stephen D Sencer | Former Officer | — | $0 | $375K | $0 | $375K |
| Sheila Sanders | Former Key Employee | 30 | $0 | $343.1K | $17.4K | $360.5K |
Paul P Marthers
Former Officer
$464K
Hrs/Wk
45
Compensation
$399.6K
Related Orgs
$0
Other
$64.3K
Greg Anderson
Former Key Employee
$450.1K
Hrs/Wk
60
Compensation
$337K
Related Orgs
$44.7K
Other
$68.4K
Liz Daunt-Samford
Former Key Employee
$432.9K
Hrs/Wk
60
Compensation
$339.8K
Related Orgs
$45.9K
Other
$47.2K
Claire Sterk
Former Officer
$408K
Hrs/Wk
40
Compensation
$365.6K
Related Orgs
$0
Other
$42.4K
Sara Shockley
Former Key Employee
$403.9K
Hrs/Wk
20
Compensation
$0
Related Orgs
$364.6K
Other
$39.3K
Stephen D Sencer
Former Officer
$375K
Hrs/Wk
—
Compensation
$0
Related Orgs
$375K
Other
$0
Sheila Sanders
Former Key Employee
$360.5K
Hrs/Wk
30
Compensation
$0
Related Orgs
$343.1K
Other
$17.4K